Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium

ABSTRACT

This invention relates to a class of heterocycles and their metal complexes, and is particularly concerned with the use of these compounds in the preparation of prodrugs or as prodrugs that may be activated under hypoxic conditions by enzymes or by therapeutic ionising radiation, in the treatment of cancer. The invention also relates to the use of these heterocycles and the corresponding metal complexes in the preparation of medicaments and to compositions including the heterocycles or their metal complexes and to methods for preparing these compounds.

[0001] The present invention relates to novel heterocycles and their metal complexes, and is particularly concerned with the use of these compounds in the preparation of prodrugs or as prodrugs that may be activated under hypoxic conditions by enzymes or by therapeutic ionising radiation, in the treatment of cancer. The present invention also relates to the use of these novel heterocycles and their metal complexes in the preparation of a medicament and to methods for preparing these compounds.

BACKGROUND TO THE INVENTION

[0002] Hypoxic regions occur widely in human tumours, and the cells in these regions are relatively resistant to ionising radiation. This leads to frequent recurrence of tumours after radiotherapy, due to the survival of these radioresistant cells. The use of oxygen-mimetic radiosensitizers has also been widely explored, but with mixed success. The existence of such hypoxic regions, restricted essentially to tumour tissue, has resulted in the development of bioreductive prodrugs (hypoxia-activated prodrugs; HAP) capable of being activated by enzymatic reduction only in these hypoxic regions. The majority of these prodrugs are activated to a transient one-electron intermediate in all cells, but this intermediate is re-oxidised by molecular oxygen in normal tissue, allowing activation to a toxic species to occur only in fully hypoxic cells.

[0003] The improved targeting ability of modem radiotherapy to deliver ionizing radiation only to the tumour field has suggested the possibility of using the reducing equivalents from this radiation, rather than cellular enzymes, to activate prodrugs (radiation-activated prodrugs; RAP). The activation of these prodrugs would thus be confined to hypoxic regions within the radiation field, providing a double level of selectivity. Such a mechanism of activation has other theoretical advantages over HAP [Wilson et al., Anticancer Drug Design, 13: 663-685, 1998]. These include:

[0004] Lack of collateral activation in partially hypoxic normal tissues (outside the radiation field).

[0005] Use of the whole of the hypoxic tumour volume (including necrotic regions with no active reductases or reducing cofactors) to activate the prodrug.

[0006] Avoidance of dependence on possibly varying enzyme levels, and degree of effectiveness as enzyme substrates.

[0007] While there have been many reports on HAP [for example reviews by Denny, Lancet Oncol. 2000, 1, 25-29; Stratford and Workman, Anti-Cancer Drug Design 1998, 13, 519-528; Denny et al., Brit. J. Cancer, 1996, Suppl. 27, 32-38], there has been relatively few reports on RAP. An approach to using therapeutic ionizing radiation to activate a prodrug was reported [Nishimoto et al., J. Med. Chem. 1992, 35, 2711; Mori et al; J. Org. Chem., 2000,65,4641-4647; Shibamoto et al., Jpn. J. Cancer Res., 2000, 91, 433-438; Shibamoto et al., Int. J. Rad. Oncol. Biol. Phys., 2001, 49,407-413], employing radiolytic activation of a 5-fluorouracil (5-FU)-based compounds, such as compound A.

[0008] However, doses of radiation used during radiotherapy (typically 2 Gy/day) provide a total primary radical yield of only approximately 1.2 μmol/kg. Only about half of this radical yield comprises reducing species capable of activating prodrugs by reduction. Thus the released effector 5-FU; illustrated as compound B above, is not sufficiently potent to ensure clinically effective concentrations following therapeutic levels of radiation.

[0009] The use of metal complexes of bidentate mustards, such as compound C illustrated below, as RAP has also been reported [Denny et al., PCT NZ96/00085, 19 Aug. 1996]. However, the released mustards, such as compound D illustrated below, are also unlikely to be sufficiently potent (IC₅₀s around 1 μM to ensure clinically effective concentrations following therapeutic levels of irradiation.

[0010] It is therefore an object of the invention to provide heterocycles and their metal complexes either as prodrugs that are activated under hypoxic conditions by enzymes or other endogenous reducing agents or by therapeutic radiation, or at least to provide the public with a useful choice.

SUMMARY OF THE INVENTION

[0011] In a first aspect, the present invention provides a class of metal complexes represented by Formula I

[0012] wherein:

[0013] A is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0014] B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₄alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0015] D is selected from C or N;

[0016] E is selected from a direct bond, OH or NR¹ ₂, where each R¹ independently represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, when D represents C; or

[0017] M is selected from Co^(III), Co^(II), Cr^(III) or Cr^(II);

[0018] Z is selected from O, NR², where R² represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups,

[0019] S¹ and S² together represent formula V

[0020] wherein X is selected from a group including CH₂-halogen, CH₂OCO—(C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups), CH₂-phosphate group or CH₂OSO₂R³, where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and

[0021] R is selected from one of formulae VI or VII

[0022] wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ or NHCOR⁵, where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or

[0023] O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4 and each R⁶ is independently selected from H or a

[0024] C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and

[0025] • represents the point of attachment of R to Formula V defined above, and

[0026] S³ is selected from H, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or hydroxy groups]; OR⁷, NR⁷ ₂, or CONHR⁷, where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or S³ represents an optionally substituted 5 or 6 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen groups, and

[0027] wherein ligands L¹-L⁴ are each independently selected in combinations from anionic monodentate ligands, including CN⁻, SCN⁻, halide, NO₃ ⁻; bidentate ligands including MeCOCHJCOMe (Jacac; deprotonated in the complex), where J=H, Me, Cl, SMe, SO₂Me, Me₂NCS₂ ⁻, S(CH₂)_(n)SO₃H, S(CH₂)_(n)CO₂H, S(CH₂)_(n)OP(O)(OH)₂, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H, CH₂(CH₂)_(n)OP(O)(OH)₂, S(CH₂)_(n)P(O)(OH)₂ or CH₂(CH₂)_(n)P(O)(OH)₂, where n is from 1-4or tridentate ligands VIIIa-VIIIc (=respectively TACH, TAME and TACN when R₁—R₃═H),

[0028] wherein each R₁-R₄ are independently selected from H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H, CH₂(CH₂)_(n)P(O)(OH)₂, CH₂(CH₂)_(n)OP(O)(OH)₂ or CH₂(CH₂)_(n)NR⁸ ₂, where each n is independently 1, 2, 3 or 4 and each R⁸ independently represents H, or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or

[0029] L¹-L⁴ can also be selected from any one of the tetradentate ligands IX-XVII, or any two of the bidentate ligands XVIII, or any combination of the bidentate ligands XVIII together with any of the monodentate ligands L¹-L⁴ defined above;

[0030] wherein in formulae IX-XVIII, R^(1′) to R^(8′) each independently represent H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H, CH₂(CH₂)_(n)P(O)(OH) or CH₂(CH₂)_(n)OP(O)(OH)₂ or CH₂(CH₂)_(n)NMe₂, where each n is independently 1, 2, 3 or 4;

[0031] each Z¹-Z⁴ is independently selected from —(CH₂)₂—, —(CH₂)₃—, —CH₂OCH₂— or —CH₂N(R⁹)CH₂—; where R⁹ represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and

[0032] each Y′ is independently selected from H, halogen, SO₂Me, O(C₁-C₆alkyl), NR¹⁰ ₂, where each R¹⁰ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or Q¹(CH₂)_(n)Q², wherein Q¹ is selected from —O—, —CH₂—, —NH—, —CONH—, —CO₂— or —SO₂—, and Q² is selected from —CO₂H, —SO₃H, —OP(O)(OH)₂ or —NR¹¹ ₂ where each R¹¹ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and

[0033] wherein the overall charge on the complex is neutral, positive or negative and wherein in the case of a non-neutral complex F^(countercharge) is selected from a range of physiologically acceptable-counterions, including halides⁻, NO₃ ⁻, NH₄ ⁺ or Na⁺; and

[0034] wherein q is the required number to neutralise the overall charge on the complex;

[0035] and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof.

[0036] Preferably, the rings A and B of a compound of Formula I as defined above together represent an 8-substituted quinoline system.

[0037] In a further aspect the present invention provides a method of providing cancer treatment, which includes the steps of

[0038] (a) administering to a patient in need of such therapy an effective amount of a compound of Formula I as defined above, and

[0039] (b) activating the compound of Formula I under hypoxic conditions via reduction, either enzymatically or by non-enzymatic endogenous reducing agents, or by ionizing radiation,

[0040] wherein said activation releases a sufficient amount of an effector from said effective amount of the compound of Formula I.

[0041] In a further aspect the present invention further provides a composition comprising as an active agent a compound of Formula I as defined above and a pharmaceutically acceptable excipient, adjuvant or carrier.

[0042] In a further aspect the present invention provides the use, in the manufacture of a medicament, of an effective amount of a compound of Formula I for use in treating a subject in need of cancer treatment.

[0043] In another aspect, the present invention provides a class of metal complexes represented by Formula Ia

[0044] wherein:

[0045] A is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0046] B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0047] D is selected from C or N;

[0048] E is selected from a 5 or 6 membered ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0049] M is selected from Co^(III), Co^(II), Cr^(III) or Cr^(II);

[0050] Z represents NH₂ or NHMe;

[0051] Q represents H, C₁₋₆alkyl or (CH₂)₂NH₂, when Q represents (CH₂)₂NH₂, Q will become a ligand for M and replace one of ligands L¹-L⁴ defined below, S¹ and S² together represent formula V

[0052] wherein X is selected from a group including CH₂-halogen, CH₂OCO—(C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups), CH₂— phosphate group or CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and

[0053] R is selected from one of formulae VI or VII

[0054] wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR², NR² ₂ where each R² independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR³ ₂, where each n is independently 1, 2, 3 or 4, and each R³ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and

[0055] • represents the point of attachment of R to Formula V defined above, and

[0056] S³ is selected from H, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or halogen groups, OR⁴, NR⁴ ₂, CONHR⁴, where each R⁴ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen groups, and

[0057] wherein ligands L¹-L⁴ are each independently selected in combinations from anionic monodentate ligands, including CN⁻, SCN⁻, halide, NO₃ ⁻; bidentate ligands including MeCOCHJCOMe (Jacac), where J=H, Me, Cl, SMe, SO₂Me, S(CH₂)_(n)SO₃H, S(CH₂)_(n)CO₂H, S(CH₂)_(n)OP(O)(OH)₂, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂)_(n)OP(O)(OH)₂, where each n is independently 1, 2, 3 or 4; or tridentate ligands VIIIa-VIIIc (=respectively TACH, TAME and TACN when R₁—R₃═H),

[0058] wherein R₁-R₄ are each independently selected from H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂)_(n)OP(O)(OH)₂ or CH₂(CH₂)_(n)NR⁵ ₂ , where each n is independently 1, 2, 3 or 4 and each R⁵ independently represents H, or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or

[0059] L¹-L⁴ can also be selected from any one of the tetradentate ligands IX-XVII, or any two of the bidentate ligands XVIII, or any combination of the bidentate ligands XVIII together with any of the monodentate ligands L¹-L⁴ defined above;

[0060] wherein in formulae IX-XVIII, R^(1′) to R^(8′) each independently represent H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂)_(n)OP(O)(OH)₂ or CH₂(CH₂)_(n)NMe₂, where each n is independently 1, 2, 3 or 4;

[0061] each Z^(1′)-Z^(4′) is independently selected from —(CH₂)₂—, —(CH₂)₃—, —CH₂OCH₂— or —CH₂N(R⁶)CH₂—; where R⁶ represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and

[0062] each Y′ is independently selected from H, halogen, SO₂Me, O(C₁-C₆alkyl), NR⁷ ₂, where each R⁷ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or Q¹(CH₂)_(n)Q², wherein Q¹ is selected from —O—, —CH₂—, —NH—, —CONH—, —CO₂— or —SO₂—, and Q² is selected from —CO₂H, —SO₃H, —OP(O)(OH)₂ or —N⁸ ₂ where each R⁸ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and

[0063] wherein the overall charge on the complex is neutral, positive or negative and wherein in the case of a non-neutral complex F^(countercharge) is selected from a range of physiologically acceptable-counterions, including halide⁻; NO₃ ⁻, NH₄ ⁺ or Na⁺; and

[0064] wherein q is the required number to neutralise the overall charge on the complex, and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof.

[0065] Preferably, the rings A and B of a compound of Formula Ia as defined above together represent an 8-substituted quinoline system.

[0066] In a further aspect the present invention provides a method of providing cancer treatment, which includes the steps of

[0067] (c) administering to a patient in need of such therapy an effective amount of a compound of Formula Ia as defined above, and

[0068] (d) activating the compound of Formula Ia under hypoxic conditions via reduction, either enzymatically or by non-enzymatic endogenous reducing agents or ionizing radiation,

[0069] wherein said activation releases a sufficient amount of an effector, from said effective amount of the compound of Formula Ia, which is of sufficient potency to kill cancer cells.

[0070] In a further aspect the present invention further provides a composition comprising as an active agent a compound of Formula Ia as defined above and a pharmaceutically acceptable excipient, adjuvant or carrier.

[0071] In a further aspect the present invention provides the use, in the manufacture of a medicament, of an effective amount of a compound of Formula Ia for use in treating a subject in need of cancer treatment.

[0072] In another aspect, the present invention provides a class of heterocycles of Formula XIX.

[0073] wherein

[0074] A is selected from a 5 or 6 membered aromatic ring system optionally containing one or more additional heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0075] B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0076] Z is selected from OH or NR¹ ₂, where R¹ separately represent H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups;

[0077] S¹ and S² together represent formula V

[0078] wherein X is selected from a group including CH₂-halogen, CH₂OCO—(C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups), CH₂-phosphate group or CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and

[0079] R is selected from one of formulae VI or VII

[0080] wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4 and each R⁶ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups;

[0081] • represents the point of attachment to Formula V defined above;

[0082] S³ is selected from H, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or hydroxy groups], OR⁷, NR⁷ ₂, CONHR⁷ where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups;

[0083] or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen groups, and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof.

[0084] with the proviso that when Z, A, B, X, S¹, S² and S³ together represent

[0085] R does not represent one of the following

[0086] Preferably, the rings A and B of a compound of Formula XIX as defined above together represent an 8-substituted quinoline system.

[0087] In a further aspect the present invention provides a method of providing cancer treatment, which includes the step of

[0088] administering to a patient in need of such therapy an effective amount of a compound of Formula XIX

[0089] wherein

[0090] A is selected from a 5 or 6 membered aromatic ring system optionally containing one or more additional heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0091] B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0092] Z is selected from OH or NR¹ ₂, where R¹ separately represent H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups;

[0093] S¹ and S² together represent formula V

[0094] wherein X is selected from a leaving group including CH₂-halogen, CH₂-phosphate group, CH₂OCO R², where R² represents C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups; CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydrogen or amino groups; and

[0095] R is selected from one of formulae VI or VII

[0096] wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4 and each R⁶ is independently selected from H or a C₁₋₆ alkyl optionally substituted with one or more hydroxy or amino groups;

[0097] • represents the point of attachment to Formula V defined above;

[0098] S³ is selected from H, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino or hydroxy groups], OR⁷, NR⁷ ₂, CONHR⁷ where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups;

[0099] or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen group, and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof.

[0100] In a further aspect the present invention provides a composition comprising as an active agent a compound of Formula XIX

[0101] wherein

[0102] A is selected from a 5 or 6 membered aromatic ring system optionally containing one or more additional heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0103] B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0104] Z is selected from O or NR¹, where R¹ represents H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups;

[0105] S¹ and S² together represent formula V

[0106] wherein X is selected from a leaving group including CH₂-halogen, CH₂-phosphate group, CH₂OCOR², where R² represents C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups; CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and

[0107] R is selected from one of formulae VI or VII

[0108] wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4 and each R⁶ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups;

[0109] • represents the point of attachment to Formula V defined above;

[0110] S³ is selected from H, OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or hydroxy groups], OR⁷, NR⁷, CONHR⁷ where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups;

[0111] or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen groups; and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof, and a pharmaceutically acceptable excipient, adjuvant or carrier.

[0112] In a further aspect the present invention provides the use, in the manufacture of a medicament, of an effective amount of formula XIX

[0113] wherein

[0114] A is selected from a 5 or 6 membered ring system optionally containing one or more additional heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0115] B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups;

[0116] Z is selected from OH or NR¹ ₂, where each R¹ independently represents H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups;

[0117] S¹ and S² together represent formula V

[0118] wherein X is selected from a leaving group including CH₂-halogen, CH₂-phosphate group, CH₂OCOR², where each R² independently represents C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups; CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁵ where R⁵ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and

[0119] R is selected from one of formulae VI or VII

[0120] wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4, and each R⁶ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups;

[0121] • represents the point of attachment to Formula XIX defined above;

[0122] S³ is selected from H, OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or hydroxy groups], OR⁷, NR⁷, CONHR⁷ where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups;

[0123] or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen groups, for use in treating a subject in need of cancer treatment, and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof.

[0124] It is to be recognised that the compounds of the invention defined above can exist in different enantiomeric and/or diastereomeric forms. In such cases it is to be understood that formulae I, Ia and XIX can represent any possible enantiomeric or diastereomeric form, or any mixtures of such forms, and also any physiologically functional salt derivatives thereof.

[0125] In a final aspect, the present invention provides methods of preparing compounds of the general formulae I, Ia and XIX defined above. Such methods are described below.

[0126] It is to be understood that the terms C₁₋₆ alkyl and C₁₋₆ alkoxy as used throughout the specification are to be taken as including both the straight and branched forms of such groups.

DESCRIPTION OF THE DRAWINGS

[0127] While the invention is broadly defined above, it will be appreciated by those skilled in the art that further aspects of the invention will become apparent with reference to the following Figure and Examples, given by way of example only, wherein

[0128]FIG. 1 shows graphically the release of a cytotoxic effector 18a (SN 26800) from a compound of Formula I M1 (SN 27892) when irradiated in formate buffer, pH 7.0 under hypoxic conditions.

[0129]FIG. 2 shows graphically the hypoxic selectivity of metal complex M1 in HT29 cultures.

DETAILED DESCRIPTION OF THE INVENTION

[0130] As defined above, this invention provides novel heterocycles and their metal complexes, and is particularly concerned with the use of these compounds, as pro drugs activated under hypoxic conditions by enzymes or by therapeutic ionising radiation, in the treatment of cancer.

[0131] In order to ensure that the complexes (pro drugs) of Formula I and Ia and the heterocycles (cytotoxins or effectors) of Formula XIX of the present invention are clinically effective, the complexes and heterocycles would preferably have the following properties

[0132] high chemical stability of the +III metal oxidation states

[0133] minimal toxicity as a prodrug prior to reductive activation by enzymes or radiation

[0134] upon activation the prodrug releases a potent cytotoxic or effector unit

[0135] Examples of pro drug complexes or heterocyclic compounds that fulfil these general criteria include the compounds of Formula I, Ia or XIX as defined above. These compounds can be prepared by the following schemes and processes as described below by way of example only.

PREPARATION EXAMPLE 1 A: Synthesis of 5-hydroxy-2,3-dihydropyrrolo[3,2-f]quinolines

[0136] In general, 5-hydroxy-2,3-dihydropyrrolo[3,2-f]quinolines of formula (XIX; Z=O) can be made from the precursor 14, that in turn can be prepared by the method outlined in Scheme 1. Conversion of the known [Curd et al., J. Chem. Soc., 1947, 69, 1613] 1 by the Skraup reaction gives 2 in 80% yield, using an improved procedure [Battersby et al., J. Chem. Soc. Perkin Trans. I, 1979, 2250]. Conversion of methyl to benzyl (2→3→4) (to allow more ready removal at the end of the synthesis), followed by reduction of 4 with Fe/AcOH gives 5. This can be BOC-protected to give 6, which can be iodinated with NIS/MeCN to give 7a or brominated (NBS/MeCN) to give 7b. Alkylation of 7a/7b with 3-bromo-1,1-dimethoxypropane gives 8a/8b, which can be deprotected (TsOH) to 9a/9b, then converted to the vinyl acetates 10a/10b (Ac₂O, DMAP, THF, reflux). These undergo radical cyclization (Bu₃SnH/AIBN) to give 11, which can be deprotected (Cs₂CO₃) to give 12. This can be converted either directly (Ph₃P, CCl₄) or via mesylate 13 (MsCl, Et₃N; then LiCl, DMF) to the desired racemic pyrroloquinoline 14.

[0137] An alternative and shorter route from 7a/7b to 14 is shown in Scheme 2. N-Alkylation of 7a/7b with 1,3-dichloropropene, and radical cyclization of the resulting vinyl chlorides 15a/15b gives 14 in high yield.

[0138] The benzyl group of 14 can be removed by hydrogenolysis (Scheme 3), and the resulting phenol 16 can be N-deprotected and coupled with appropriate side chains R (formula XIX). An alternative route is by N-deprotection/coupling, followed by removal of the benzyl group (14→17→18), either by hydrogenolysis or by acid treatment.

PREPARATION EXAMPLE 2 Synthesis of 5-amino-2,3-dihydropyrrolo[3 2-f]quinolines

[0139] In general, 5-amino-2,3-dihydropyrrolo[3,2-f]quinolines (XIX, Z represents NH₂) can be prepared from the precursor 25, which can be synthesized by the method outlined in Scheme 4. The quinoline acid 19 [Jung et al., Eur. Pat. Appln. EP 581500 (1994); Chem Abstr, 1994, 122, 205125], prepared by a Skraup reaction on ethyl 4-amino-3-nitrobenzoate, is converted with DPPA/t-BuOH/Et₃N to the quinoline 20. Nitro group reduction gives amine 21, which is converted to the phthaloyl derivative 22, and then brominated (NBS/MeCN) to give 23. N-Alkylation of this with 1,3-dichloropropene, followed by radical cyclisation of the resulting chloro intermediate 24 with Bu₃SnH/AIBN, gives the tricyclic pyrroloquinolinone 25. As shown in Scheme 4, NBOC deprotection of 25 followed by EDCI coupling with acids gives the compounds of formula 26 (illustrated for the example where R=5,6,7-trimethoxyindol-2-yl). Finally, deblocking of compound 26 by hydrazinolysis gives compounds of formula XIX, where Z represents NH₂ (illustrated for the example where R=5,6,7-trimethoxyindol-2-yl; 27).

PREPARATION EXAMPLE 3 Synthesis of 5-(2-aminoethylamino)benz[e]indoles

[0140] These can be prepared from the appropriate 5-amino compounds by condensation with the BOC-protected aminoacetaldehye, followed by reduction with sodium cyanoborohydride or other suitable reductants, and deprotection of the BOC group. Scheme 5 shows the synthesis of the representative compound 29 from the known [Atwell et al., J. Org. Chem. 1998, 63, 9414-9420] 5-amino compound 28. It will be appreciated that this synthesis can also be applied to the preparation of the analogous derivative from the 5-aminoaza compound 27.

PREPARATION EXAMPLE 4 Synthesis of Ancillary Ligands

[0141] As an example of the synthesis of new ancillary cyclen-type tetradentate ligands, reaction of perhydro-3,6,9,12-tetraazacyclopenteno[1,3-f,g]acenaphthylene (30) [Weisman et al, Tetrahedron Lett, 21, 1980, 335] with 1,3-propanesultone gives the bis-quaternary salt (31), which is treated with hydrazine monohydrate to give the bis(propanesulfonic acid) (32) (Scheme 6). It will be appreciated that similar reaction of 30 with other alkylating reagents will give other analogues, such as those represented as compounds 33 to 36 in Scheme 6.

PREPARATION EXAMPLE 5 Synthesis of Metal Complexes

[0142] As an example of the synthesis of metal complexes of Formula I defined above, using a tetradentate ancillary ligand, reaction of complex 39 bearing labile triflate ligands with 18a gives the Co^(III) complex M1, as illustrated in Scheme 7.

[0143] As an example of the synthesis of metal complexes of Formula Ia defined above, using bidentate ancillary ligands, reaction of 18a with [Cr(acac)₂(H₂O)₂]CO₄].2H₂O in dry CH₃CN gives the desired Cr(acac)₂-18a complex M4. This reaction pathway is represented in Scheme 8. Similar reaction of 29 gives the corresponding Cr(acac)₂-29 complex M6.

[0144] Cr^(III) complexes with other tetradentate macrocycles may be prepared by a similar synthetic route to that employed in the example above using Co^(III), in that the key intermediate for both is a reactive bis[triflato] complex (or a solvent species in solution). The use of nitro complexes as precursors to triflato complexes is unlikely for Cr^(III), as nitro is a poor ligand on Cr^(III). Instead, chloro complexes serve the purpose well. In the strongly acidic triflic acid, protonation of coordinated Cl⁻ is significant and leads to labilization and ligand loss, made irreversible by removal of the gaseous HCl co-product.

[0145] As an example of metal complexes with tridentate ligands, reaction of the triamine TACN with Na₃[Co(NO₂)₆] gives the complex [Co(TACN)(H₂O)₃].(OTf)₃ (Scheme 9). Reaction of this with the model quinoline 8-hydroxyquinline (8-HQ) gives complex M7.

EXAMPLES OF THE INVENTION

[0146] The following examples of metal complexes M1-M9 in Table 1 are representative of the complexes of the invention and can be prepared by the detailed processes of the invention described after the table.

[0147] Table 1. Structures and Physical Properties of Metal Complexes toxic No Metal ligand Ancillary ligands Analyses M1 Co^(III) 18a Cyclen (IX; Z¹-Z⁴ = − C₃₂H₄₁N₇ ³⁵ClCoO₅ (CH₂)₂−, R^(1′)-R^(4′) = H) [M-2ClO₄-H]⁺ Calc: 697.21897 Fd: 697.21327 M2 Co^(III) 18c Cyclen (IX; Z¹-Z⁴ = − C₃₃H₄₅ ³⁵ClCoN₇O₃ (CH₂)₂−, R^(1′)-R^(4′) = H) [M-2OTf]⁺ Calc: 681.26044. Fd: 681.26064 M3 Co^(III) 18b Cyclen (IX; Z¹-Z⁴ = − C₃₃H₄₄ ³⁵ClCoN₈O₃ (CH₂)₂−, R^(1′)-R^(4′) = H) [M-2OTf]⁺ Calc: 694.25569. Fd: 694.25305 M4 Cr^(III) 18a (Acac)₂ C₃₄H₃₆N₃ ³⁵ClCrO₉ (MeCOCH₂COMe)₂ [M + H]⁺ Calc: 717.15452 Fd: 717.15198 M5 Co^(III) 18a (Me₂dithiocarbamato)₂ (Me₂NSC₂)₂ M6 Cr^(III) 29 (Acac)₂ C₃₇H₄₃N₄ ³⁵ClCrO₈ (MeCOCH₂COMe)₂ [M-ClO₄]⁺ Calc: 758.21745 Fd: 758.21834 M7 Co^(III) 8-HQ TACN (VIIIc: R¹-R³ = H))

Example A Preparation of 1-(chloromethyl)-5-hydroxy-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (18a) and Analogues 18b-18f by the Methods of Schemes 1-3.

[0148] 8-Hydroxy-6-nitroquinoline Hydrobromide (3).

[0149] A solution of 8-methoxy-6-nitroquinoline (2) [prepared from 2-methoxy-4-nitroaniline 1 by the method of Battersby et al., J. Chem., Soc. Perkin Trans. 1, 1979,2550] (50.0 g, 0.245 mol) in 48% aqueous HBr (0.205 L, 1.22 mol) was stirred at reflux for 65 h. The mixture was cooled in ice and the precipitate was removed by filtration and dried in a desiccator to give 3 as the hydrobromide salt (58.0 g, 87%): subl. 140° C., mp>230° C; ¹H NMR (DMSO) δ 10.69 (br s, 2 H), 9.20 (dd, J=4.9, 1.5 Hz, 1H), 9.11 (dd, J=8.5, 1.5 Hz, 1 H), 8.64(d, J=2.4 Hz, 1 H), 8.05 (dd, J=8.5, 4.9 Hz, 1 H), 7.90 (d, J=2.4 Hz, 1 H); ¹³C NMR (DMSO) δ 152.0, 149.4, 146.4, 144.3, 135.4, 128.3, 124.1, 114.5, 106.5. Anal. Calcd for C₉H₆N₂O₃.HBr: C, 40.01; H, 2.61; N, 10.37. Found: C, 40.44; H, 2.17; N, 10.83.

[0150] 8-Benzyloxy-6-nitroquinoline (4).

[0151] A mixture of 3 (58.0 g, 0.214 mol), DMF (400 mL), K₂CO₃ (103.5 g, 0.75 mmol), and NaI (1.60 g, 10.7 mmol) was stirred at room temperature, while benzyl bromide (25.4 mL, 0.214 mmol) was added in four portions at half hourly intervals. A total of 9 h after the first addition, the mixture was poured onto ice (1.5 kg) and the precipitate was removed by filtration, washed with water, and dried. The crude material was dissolved in CH₂Cl₂ and the solution was filtered through alumina to give 4 (59.55 g, 99%): mp (EtOH) 152-153° C.; ¹H NMR (CDCl₃) δ 9.13 (dd, J=4.2, 1.8 Hz, 1 H), 8.35 (d, J=2.3 Hz, 1 H), 8.29 (dd, J=8.4, 1.8 Hz, 1 H), 7.83 (d, J=2.3 Hz, 1 H), 7.59 (dd, J=8.4, 4.2 Hz, 1 H), 7.56 (d, J=7.6 Hz, 2 H), 7.40 (dd, J=7.6, 7.2 Hz, 2 H), 7.33 (t, J=7.2 Hz, 1 H), 5.50 (s, 2 H); ¹³C NMR (CDCl₃) δ 155.4, 152.5, 145.6, 142.6, 137.9, 135.4, 128.8, 128.4, 127.8, 127.5, 123.3, 116.3, 103.1, 71.4. Anal. Calcd. for C₁₆H₁₂N₂O₃: C, 68.57; H, 4.32; N, 9.99. Found: C, 68.51; H, 4.29; N, 10.04.

[0152] 6-Amino-8-benzyloxyquinoline (5).

[0153] Iron dust (16.0 g, 0.285 mol) was added to a solution of 4 (8.00 g, 28.5 mmol) and AcOH (16 mL, 0.285 mol) in EtOH-water (5:1, 240 mL) at reflux. After 10 min, the mixture was carefully poured into saturated aqueous NaHCO₃ (300 mL). The mixture was filtered through Celite and the filter cake was washed with water (100 mL), EtOH (3×50 mL), and CH₂Cl₂ (3×100 mL). The combined filtrates were diluted with water (300 mL) and the aqueous layer was separated and extracted with CH₂Cl₂ (2×50 mL). The combined extracts were washed with water, dried (Na₂SO₄), and evaporated to give 5 (7.13 g, 100%) as a tan solid: mp 183-185° C.; ¹H NMR (CDCl₃) δ 8.66 (dd, J=4.2, 1.6 Hz, 1 H), 7.84 (dd, J=8.3, 1.6 Hz, 1 H), 7.48 (dd, J=8.1, 1.7 Hz, 2 H), 7.23-7.39 (m, 3 H), 7.28 (dd, J=8.3, 4.2 Hz, 1 H), 6.51, 6.48 (2×d, J=2.3 Hz, 1 H each), 5.36 (s, 2 H), 3.85 (br s, 2 H); ¹³C NMR (CDCl₃) δ 155.2, 155.7, 144.8, 136.8, 135.9, 133.5, 130.8, 128.6, 127.8, 127.0, 122.0, 102.6, 100.0, 70.6. Anal. Calcd for C₁₆H₁₄N₂O: C, 76.78; H, 5.64; N, 11.19. Found C, 76.54; H, 5.61; N, 11.15.

[0154] 8-Benzyloxy-6-(tert-butyloxycarbonylamino)quinoline (6).

[0155] A mixture of 5 (7.63 g, 30.5 mmol), BOC₂O (8.65 g, 39.6 mmol) and dioxane (70 mL) was stirred at reflux for 2 h. Further BOC₂O (0.86 g, 4.0 mmol) was added and the mixture was heated at reflux for another 1 h. The dioxane was evaporated, the remaining oil was triturated with pentane, and the resulting solid was removed by filtration, dissolved in CH₂Cl₂ and filtered through alumina to give 6 (10.42 g, 98%) as a cream solid: mp 180-181° C.; ¹H NMR (CDCl₃) δ 8.77 (dd, J=4.2, 1.6 Hz, 1 H), 7.98 (dd, J=8.3, 1.6 Hz, 1 H), 7.55 (d, J=2.1 Hz, 1 H), 7.41 (dd, J=7.4, 2.2 Hz, 2 H), 7.34 (dd, J=8.3, 4.2 Hz, 1 H), 7.20-7.29 (m, 3 H), 7.02 (d, J=2.1 Hz, 1 H), 5.28 (s, 2 H), 1.49 (s, 9 H); ¹³C NMR (CDCl₃) δ 154.6, 152.7, 147.4, 137.2, 136.8, 136.3, 135.2, 129.9, 128.4, 127.7, 127.2, 122.0, 105.8, 103.5, 80.6, 70.6, 28.2. Anal. Calcd for C₂₁H₂₂N₂O₃: C, 71.98; H, 6.33; N, 7.99. Found C, 71.80; H, 6.31; N, 7.98.

[0156] 8-Benzyloxy-6-(tert-butyloxycarbonylamino)-5-iodoquinoline (7a).

[0157] A mixture of 6 (1.04 g, 3.0 mmol), NIS (0.70 g, 3.1 mmol) and CH₃CN (10 mL) was stirred at reflux for 30 min. Further NIS (40 mg, 0.18 mmol) was added and the mixture stirred at reflux for a further 30 min. The CH₃CN was evaporated and the residue was taken up in EtOAc (30 mL) and washed with a solution of Na₂S₂O₅ and Na₂CO₃ in water (×3). The aqueous washes were back extracted with EtOAc (×2). The combined organic extracts were washed with water, dried (brine, MgSO₄), filtered through silica gel, and evaporated to give 7a (1.33 g, 93%), which crystallized from hexane as tan needles: mp 118-119° C.; ¹H NMR (CDCl₃) δ 8.79 (dd, J=4.2, 1.4 Hz, 1 H), 8.32 (dd, J=8.6, 1.4 Hz, 1 H), 8.29 (s, 1 H), 7.59 (dd, J=8.0, 1.7 Hz, 2 H), 7.43 (dd, J=8.6, 4.2 Hz, 1 H), 7.25-7.39 (m, 3 H), 7.24 (br s, 1 H), 5.43 (s, 2 H), 1.57 (s, 9 H); ¹³C NMR (CDCl₃) δ 155.2, 152.4, 148.1, 139.5, 138.9, 138.3, 136.2, 130.7, 128.5, 128.0, 123.4, 103.9, 81.5, 78.1, 71.0, 28.3. Anal. Calcd for C₂₁H₂₁IN₂O₃: C, 52.96; H, 4.44; N, 5.88. Found C, 53.18; H, 4.39; N, 5.95.

[0158] 8-Benzyloxy-6-[N-(tert-butyloxycarbonyl)-N-(3,3-dimethoxypropyl)amino]-5-iodoquinoline (8a).

[0159] NaH (60% in oil, 92 mg, 2.3 mmol) under nitrogen was washed with pentane (2×2 mL), cooled (ice-water) and treated with a solution of 7a (1.00 g, 2.10 mmol) in DMF (10 mL) over 5 min. The mixture was allowed to warm to room temperature and stir for 30 min, over which time it became bright yellow and effervescence ceased A solution of 3-bromo-1,1-dimethoxypropane (0.69 g, 3.77 mmol) in DMF (0.5 mL) was added and the mixture was stirred at room temperature for 22 h. The mixture was poured into pH 7.4 phosphate buffer (50 mL) and extracted with EtOAc (3×20 mL). The combined extracts were washed with water (2×50 mL), dried (brine, Na₂SO₄), evaporated, and purified by dry-flash column chromatography (silica gel, 10-90% EtOAc/hexane), to give 8a (1.00 g, 83%) as a cream powder: mp 120-121° C.; ¹H NMR (CDCl₃) major rotamer δ 8.94 (br d, J=2.9 Hz, 1 H), 8.52 (dd, J=8.6, 1.5 Hz, 1 H), 7.45-7.58 (m, 3 H), 7.25-7.40 (m, 3 H), 6.96 (br s, 1 H), 5.46 (s, 2 H), 4.40 (t, J=4.7 Hz, 1 H), 3.84 (br ddd, J=14.6, 7.3, 7.3 Hz, 1 H), 3.33 (ddd, J=14.6, 8.2, 5.8 Hz, 1 H), 3.28, 3.25 (2×s, 3 H each), 1.65-1.95 (m, 2 H), 1.23 (br s, 9 H); ¹³C NMR (CDCl₃) major rotamer δ 154.6, 153.6, 149.9, 143.8, 141.3, 139.8, 136.0, 131.2, 128.7, 128.0, 127.0, 123.4, 112.3, 102.9, 93.3, 80.3, 70.9, 53.1, 52.7, 45.4, 31.2, 28.1; C₂₆H₃₁IN₂O₅ requires M⁺. 578.1278. Found 578.1257.

[0160] 8-Benzyloxy-6-[N-(tert-butyloxycarbonyl)-N-(3-oxopropyl)amino]-5-iodoquinoline (9a).

[0161] A solution of 8a (0.75 g, 1.30 mmol), TsOH.H₂O (0.12 g, 0.65 mmol) and water (3.75 mL) in acetone (38 mL) was stirred at reflux for 2.25 h. Most of the acetone was evaporated and the residue was diluted with water (50 mL) and saturated aqueous NaHCO₃ (5 mL) and extracted with EtOAc (3×20 mL). The combined extracts were washed with water (2×50 mL), dried (Na₂SO₄), and evaporated to give 9a (0.68 g, 99%) as a pale yellow foam; ¹NMR (CDCl₃) major rotamer δ 9.68 (s, 1 H), 8.97 (dd, J=4.2, 1.5 Hz, 1 H),8.51 (dd, J=8.6, 1.5 Hz, 1 H), 7.53 (dd, J=8.6, 4.2 Hz, 1 H), 7.47-7.55 (m, 2 H), 7.25-7.40 (m, 3 H), 6.87 (br s, 1 H), 5.49 (s, 2 H), 4.17 (br dt, J=14.5, 7.1 Hz, 1 H), 3.59 (dt, J=14.5, 6.5 Hz, 1 H), 2.57 (br dd, J=7.1, 6.5 Hz, 2 ), 1.23 (s, 9 H); ¹³C NMR (CDCl₃) major rotamer δ 200.3, 154.8, 153.4, 150.0, 143.0, 141.0, 139.7, 135.9, 131.0, 128.6, 127.9, 127.0, 123.4, 112.1, 93.1, 80.7, 70.7, 42.9, 42.5, 27.9; C₂₄H₂₅IN₂O₄ requires M^(+.) 532.0859. Found 532.0862.

[0162] 6-[N-(3-Acetoxy-2-propenyl)-N-(tert-butyloxycarbonyl)amino]-8-benzyloxy-5-iodoquinoline (10a).

[0163] A mixture of 9a (0.62 g, 1.16 mmol), Et₃N (0.40 mL, 2.87 mmol), Ac₂O (0.25 mL, 2.65 mmol), DMAP (14 mg, 0.11 mmol), and THF (12 mL) was stirred at reflux for 2 h. Further Et₃N (0.80 mL, 5.74 mmol), Ac₂O (0.50 mL, 5.3 mmol), and DMAP (10 mg, 0.08 mmol) were added and heating was continued for a further 2 h. The solvent was evaporated, and the residue was diluted with pH 7.4 phosphate buffer (50 mL) and extracted with EtOAc (3×20 mL). The combined extracts were washed with water (50 mL), dilute aqueous NaHCO₃ (50 mL), and water (50 mL) before being dried (brine, Na₂SO₄), and evaporated. The residue was purified by dry-flash column chromatography (silica gel, 10-80% EtOAc-hexane) to give 10a (0.54 g, 81%) as a white foam, which contained a 1:4 mixture of Z and E isomers: ¹H NMR (CDCl₃) major rotamer δ 8.94 (br s, 1 H), 7.45-7.55 (m, 3 H), 7.27-7.40 (m, 3 H), 6.84-7.12 (m, 2 H), 5.36-5.58 (m, 2.8 H), 4.91 (ddd, J=7.6, 6.5, 5.9 Hz, 0.2 H), 4.57 (dd, J=15.0, 5.9 Hz, 0.2 H), 4.39 (dd, J=14.7, 6.8 Hz, 0.8 H), 4.06 (dd, J=15.0, 7.6 Hz, 0.2 H), 3.86 (dd, J=14.7, 7.9 Hz, 0.8 H), 2.08 (s, 2.4 H), 1.88 (s, 0.6 H), 1.57 (br s, 1.8 H), 1.26 (br s, 7.2 H); ¹³C NMR (CDCl₃) major rotamer δ 167.4, 167.0, 154.5, 149.8, 154.3, 149.8, 153.3, 153.1,142.8, 140.9, 139.7, 138.8, 139.7, 143.1, 135.8, 130.9, 136.0, 127.8, 126.8, 126.7, 128.4, 123.2, 112.1, 112.0, 109.1, 108.2, 93.5, 93.1, 80.9, 80.4, 70.8, 70.7, 46.4, 42.7, 27.9, 28.1, 20.3, 20.1; C₂₆H₂₇IN₂O₅ requires M^(+.) 574.0965. Found 574.0962.

[0164] 1-(Acetoxymethyl)-5-benzyloxy-3-(tert-butyloxycarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (11).

[0165] A solution of 10a (0.54 g, 0.94 mmol), AIBN (15 mg, 0.09 mmol), and Bu₃SnH (0.32 g, 1.13 mmol) in benzene (45 mL) was stirred at reflux under nitrogen for 5.5 h. The solvent was evaporated, the residue was triturated with pentane, and the precipitate was collected by filtration to give 11 (0.32 g, 77%), which crystallized from MeOH as fluorescent pale yellow rectangular plates: mp 172-173° C.; ¹H NMR (CDCl₃) δ 8.82 (dd, J=4.1, 1.4 Hz, 1 H), 8.14 (dd, J=8.4, 1.4 Hz, 1 H), 8.07 (br S, 1 H), 7.55 (br s, 2 H), 7.41 (dd, J=8.4, 4.1 Hz, 1 H), 7.36 (dd, J=7.3,7.3 Hz, 2 H), 7.30 (tt, J=7.3, 2.4 Hz, 1 H), 5.44, 5.39 (2×d, J=12.5 Hz, 1 H each), 4.42-4.52 (m, 1 H), 4.05-4.14 (m, 2 H), 3.82-3.93 (m, 2 H), 2.08 (s, 3 H), 1.57 (s, 9 H); ¹³C NMR (CDCl₃) δ 171.0, 155.2, 152.3, 146.9, 142.0 (br), 137.0, 136.3, 131.1, 128.5, 127.9, 127.7, 126.0, 122.1, 113.3 (v. br), 100.4 (br), 81.4 (br), 70.7, 65.8, 52.6, 37.7, 28.4, 20.9. Anal. Calcd for C₂₆H₂₈N₂O₅: C, 69.63; H, 6.29; N, 6.25. Found: C, 69.46; H, 6.27; N, 6.30.

[0166] 5-Benzyloxy-3-(tert-butyloxycarbonyl)-1-(hydroxymethyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (12).

[0167] A mixture of 11 (0.22 g, 0.50 mmol), Cs₂CO₃ (0.42 g, 1.29 mmol), and EtOH-water (2:1, 6 mL) was stirred at reflux for 30 min. The mixture was diluted with EtOAc (30 mL) and dilute aqueous NaHCO₃ (50 mL). The separated aqueous phase was extracted with EtOAc (30 mL). The combined extracts were washed with water (3×50 mL), dried (brine, Na₂SO₄), and evaporated to give 12 (0.19 g, 95%), which crystallized from MeOH as tiny white needles: mp 170-171° C.; ¹H NMR (CDCl₃) δ 8.54 (br s, 1 H), 7.99 (br d, J=8.0 Hz, 1 H), 7.91 (br s, 1 H), 7.55 (d, J=6.6 Hz, 2 H), 7.20-7.40 (m, 4 H), 5.29 (s, 2 H), 4.00-4.22 (m, 2 H), 3.65-3.78 (m, 3 H, H-1), 3.23 (br s, 1 H), 1.56 (s, 9 H); ¹³C NMR (CDCl₃) δ 154.4, 152.5 (br), 146.2 (br), 142.2 (v. br), 136.3, 136.2, 131.3, 128.5, 128.0 (v. br), 127.9, 125.9, 121.6, 114.7 (v. br), 100.4 (br), 81.0 (br), 70.7, 64.6, 52.3, 40.9 (br), 28.4. Anal. Calcd. for C₂₄H₂₆N₂O₄.H₂O: C, 67.91; H, 6.65; N, 6.60. Found: C, 68.16; H, 6.47; N, 6.71.

[0168] 5-Benzyloxy-1-(methylsulfonyloxymethyl)-3-(tert-butyloxycarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (13).

[0169] MsCl (0.06 mL, 0.7 mmol) was added to a cooled (ice-water) solution of 12 (0.17 g, 0.41 mmol) and Et₃N (0.2 mL, 1.4 mmol) in CH₂Cl₂ (3 mL) and the mixture was stirred for 30 min. The CH₂Cl₂ was evaporated and the residue was stirred with water (25 mL) for 10 min. The mixture was extracted with EtOAc (2×25 mL). The combined extracts were washed with water (2×50 mL), dried (Na₂SO₄), and evaporated to give 13 (0.17 g, 86%), which crystallized from MeOH as tiny cream needles: mp 156-157° C.; ¹H NMR (CDCl₃) δ 8.80 (dd, J=4.2, 1.4 Hz, 1 H), 8.02 (dd, J=8.7, 1.4 Hz, 1 H 7.97 (br s, 1 H), 7.55 (br d, J=6.9 Hz, 2 H), 7.41 (dd, J=8.7, 4.2 Hz), 7.25-7.38 (m, 3 H), 5.40 (s, 2 H), 4.46 (dd, J=9.8, 3.7 Hz, 1 H), 3.93-4.24 (m, 4 H), 2.90 (s, 3 H), 1.57 (s, 9 H); ¹³C NMR (CDCl₃) δ 155.6, 152.1, 147.0, 141.0 (v. br), 137.1, 136.1, 130.5, 128.4, 127.9, 127.6 (br), 125.7, 122.3, 112.7 (v. br), 100.3, 81.6 (br), 70.7, 69.9, 52.0, 38.2 (br), 37.4, 28.3. Anal. Calcd for C₂₅H₂₈N₂O₆S: C, 61.97; H, 5.82; N, 5.78; S, 6.62. Found: C, 62.15; H, 5.96; N, 5.88; S, 6.54.

[0170] 5-Benzyloxy-3-(tert-butyloxycarbonyl)-1-(chloromethyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (14). Method 1.

[0171] A mixture of 13 (50 mg, 0.10 mmol), LiCl (25 mg, 0.59 mmol), and DMF (0.25 mL) was stirred at 80° C. for 1 h, before ice (3 g) was added. The precipitate was removed by filtration, washed with water, and taken up in EtOAc (20 mL). This solution was washed with water (20 mL), dried (Na₂SO₄), and evaporated to give 14 (39 mg, 89%), which crystallized from MeOH as fluorescent cream needles: mp 178-179° C.; ¹H NMR (CDCl₃) δ 8.82 (dd, J=4.2, 1.5 Hz, 1 H), 8.05 (br s, 1 H), 7.99 (br d, J=8.4 Hz, 1 H), 7.55 (br s, 2 H), 7.41 (dd, J=8.4, 4.2 Hz, 1 H), 7.35 (dd, J=7.3, 7.3 Hz, 2 H), 7.30 (tt, J=7.3, 2.4 Hz, 1 H), 5.42, 5.38 (2×d, J=12.4 Hz, 1 H each), 4.23 (br d, J=11.7 Hz, 1 H), 4.12 (dd, J=11.7, 8.9 Hz, 1 H), 3.92 (dddd, J=10.1, 8.9, 3.2, 2.6 Hz, 1 H), 3.81 (dd, J=11.1, 3.2 Hz, 1 H), 3.45 (dd, J=11.1, 10.1Hz, 1 H), 1.56 (s, 9 H); ¹³C NMR (CDCl₃)δ 155.5, 152.3, 146.9, 141.9(br), 137.1, 136.3, 130.3, 128.5, 127.9, 127.7 (br), 125.6, 122.2, 113.4 (v. br), 100.4 (br), 81.6 (br), 70.8, 53.0, 46.3, 41.1, 28.4. Anal. Calcd. for C₂₄H₂₅ClN₂O₃: C, 67.84; H, 5.93; Cl, 8.34; N, 6.59. Found: C, 67.85; H, 5.94; N, 6.68; Cl, 8.26.

[0172] 8-Benzyloxy-6-[N-(tert-butyloxycarbonyl)-N-(3-chloro-2-propenyl)amino]-5-iodoquinoline (15a).

[0173] NaH (60% dispersion in oil, 0.26 g, 6.5 mmol) under nitrogen was washed with pentane (3×2 mL), cooled (ice-water), and treated with a solution of 7a (2.80 g, 5.88 mmol) in DMF (28 mL) over 5 min. The cooling bath was removed and the mixture was allowed to stir for 30 min, by which time the solution was deep yellow and effervescence had ceased. 1,3-Dichloropropene (0.98 g, 8.82 mmol) was added and the mixture was stirred for 86 h The mixture was diluted with water (150 mL) and extracted with EtOAc (4×25 mL). The combined extracts were washed with water (3×100 mL), dried (brine, Na₂SO₄), and evaporated. The residue was triturated with pentane and the precipitate was collected by filtration to give 15a (3.02 g, 93%) as a tan powder: mp 115-135° C. containing a 1:1 mixture of Z and E isomers; ¹H NMR (CDCl₃) major rotamer δ 8.95 (br s, 1 H), 8.50 (dd, J=8.4, 2.5 Hz, 1 H), 7.46-7.55 (m, 3 H), 7.27-7.41 (m, 3 H), 6.79-6.96 (m, 1 H), 5.30-6.03 (m, 4 H), 4.54 (dd, J=15.5, 5.6 Hz, 0.5 H), 4.38 (dd, J=14.8, 6.8 Hz, 0.5 H), 4.18 (dd, J=15.5, 6.9 Hz, 0.5 H), 3.79 (dd, J=14.8, 7.8 Hz, 0.5 H), 1.23-1.82 (m, 9 H); ¹³C NMR (CDCl₃) major rotamer δ 154.7, 155.2, 153.6, 153.3, 150.2, 150.1, 143.2, 142.8, 141.2, 140.2, 136.2, 136.0, 131.13, 131.08, 128.79, 128.73, 128.12, 127.99, 127.2, 126.6, 126.98, 126.90, 123.5, 123.4, 122.0, 121.1, 112.2, 111.9, 93.65, 93.58, 80.90, 80.85, 71.0, 70.9, 48.8, 45.4, 28.4, 28.1. C₂₄H₂₄ClIN₂O₃ requires M^(+.) 550.0520, 552.0491. Found 550.0536, 552.0503. Purification of the mother liquors by dry-flash column chromatography (silica gel, 10-60% EtOAc-hexane) gave further 15a (0.14 g, 4%).

[0174] Compound 14 by Method 2.

[0175] A solution of 15a (3.90 g, 5.45 mmol), AIBN (89 mg, 0.54 mmol), and Bu₃SnH (1.75 g, 6.0 mmol) in benzene (270 mL) was heated at reflux under nitrogen for 3 h. The benzene was evaporated, the residue was triturated with pentane, and the precipitate was collected by filtration to give 14 (2.21 g, 95%), identical to the material prepared above.

[0176] Compound 14 by Method 3.

[0177] A mixture of 12 (19 mg, 0.047 mmol), Ph₃P (37 mg, 0.14 mmol) and CH₂Cl₂ (0.4 mL) was treated with CCl₄ (0.05 mL, 0.52 mmol), and the mixture was stirred under nitrogen for 4 h. The mixture was diluted with dilute aqueous NaHCO₃ (5 mL) and extracted with EtOAc (3×5 mL). The combined extracts were dried (Na₂SO₄), evaporated, and purified by dry-flash column chromatography (silica gel, 10-90% EtOAc/hexane) to give 14 (20 mg, 100%) identical with the material prepared above.

[0178] 3-(tert-Butyloxycarbonyl)-1-(chloromethyl)-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (16).

[0179] A cooled (ice-water) mixture of 14 (0.11 g, 0.27 mmol), 10% Pd/C (55 mg), and TBF (5 mL) under nitrogen was treated with 25% aqueous NH₄HCO₃ (0.67 mL). The mixture was stirred at 0° C. for 6 h, and was then diluted with EtOAc (20 mL), dried (Na₂SO₄), filtered through Celite, evaporated, and purified by dry-flash column chromatography (silica gel, 10-50% EtOAc/hexane) to give 16 (39 mg, 44%) as a white solid: mp 148-149° C.; ¹H NMR (CDCl₃) δ 8.61 (dd, J=4.2, 1.2 Hz, 1 H),8.01 (dd, J=8.5, 1.2 Hz, 1 H), 7.83 (br s, 1 H), 7.41 (dd, J=8.5, 4.2 Hz, 1 H), 4.26 (dd, J=11.8, 2.2 Hz, 1 H), 4.14 (dd, J=11.8, 8.5 Hz, 1 H), 3.93 (dddd, J=9.8, 8.5, 3.2, 2.2 Hz, 1 H), 3.80 (dd, J=11.1, 3.2 Hz, 1 H), 3.46 (dd, J=11.1, 9.8 Hz, 1 H), 1.61 (s, 9 H); ¹³C NMR (CDCl₃) δ 153.5, 152.3, 145.3, 142.4 (br), 135.0, 130.6, 124.9, 122.6, 112.4 (v. br), 100.0, 81.7 (br), 53.0, 46.5, 40.9, 28.4. C₁₇H₁₉ClN₂O₃ requires M^(+.) 334.1084, 336.1055. Found 334.1081, 336.1058.

[0180] 5-Benzyloxy-1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (17a).

[0181] A suspension of 14 (0.65 g, 1.53 mmol) in dioxane (40 mL) was saturated with HCl, allowed to stand for 1 h, and evaporated. 5,6,7-Trimethoxyindole-2-carboxylic acid (0.38 g, 1.53 mmol), EDCI (0.88 g, 4.6 mmol) and DMA (25 mL) were added to the remaining green-yellow solid, and the red mixture was stirred at room temperature for 39 h. The mixture was poured into a mixture of ice (60 g) and pH 7.4 phosphate buffer (60 mL). The precipitate was removed by filtration, washed with water, and taken up in EtOAc (60 mL). This solution was washed with water (3×50 mL), dried (brine, Na₂SO₄), and evaporated. The remaining oil was triturated with Et₂O. The precipitate was collected by filtration, purified by flash column chromatography (silica gel, EtOAc), and triturated with Et₂O to give 17a (0.38 g, 44%) as a pale yellow solid: mp 182-184° C.; ¹H NMR (CDCl₃) δ 9.59 (s, 1 H), 8.84 (dd, J=4.2, 1.6 Hz, 1 H), 8.37 (s, 1 H), 7.95 (dd, J=8.5, 1.6 Hz, 1 H), 7.58 (br d, J=7.2 Hz, 2 H), 7.38 (dd, J=8.5, 4.2 Hz, 1 H), 7.36 (dd, J=7.3, 7.2 Hz, 2 H), 7.30 (t, J=7.3 Hz, 1 H), 6.93 (d, J=2.2 Hz, 1 H), 6.84 (s, 1 H), 5.48, 5.42 (2×d, J=12.5 Hz, 1 H each), 4.69 (dd, J=10.8, 1.9 Hz, 1 H), 4.57 (dd, J=10.8, 8.5 Hz, 1 H), 4.06, 3.93, 3.90 (3×s, 3 H each), 4.02 (dddd, J=10.3, 8.5, 3.2, 1.9 Hz, 1 H), 3.83 (dd, J=11.4, 3.2 Hz, 1 H), 3.42 (dd, J=11.4, 10.3 Hz, 1 H); ¹³C NMR (CDCl₃) δ 160.5, 155.3, 147.8, 150.2, 142.3, 140.6, 138.8, 138.2, 129.5, 125.1, 123.5, 136.4, 130.4, 128.6, 128.0, 127.7, 125.6, 122.3, 115.3, 106.7, 102.3, 97.6, 70.8, 61.4, 61.1, 56.2, 55.1, 45.9, 42.5. C₃₁H₂₈ClN₃O₅ requires M+H 558.1796, 560.1766. Found (FAB) 558.1770, 560.1786. Anal. Calcd for C₃₁H₂₈ClN₃O₅: C, 66.72; H, 5.06; N, 7.53. Found: C, 66.96; H, 5.36; N, 7.50.

[0182] 1-(Chloromethyl)-5-hydroxy-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (18a). Method 1.

[0183] THF (10 mL) then 25% aqueous NH₄HCO₃ (1.1 mL) were added to a cooled (ice-water) mixture of 17a (0.25 g, 0.45 mmol) and 10% Pd/C (0.13 g) under nitrogen. The mixture was stirred at 0° C. for 7.5 h, and was then filtered through Celite. The Celite was washed with a solution of concentrated HCl (2 mL) and MeOH (40 mL) and then with CH₂Cl₂—MeOH (3:1, 40 mL). The combined filtrates were diluted with water (40 mL) and CH₂Cl₂ (30 mL) and neutralized with pH 7.4 phosphate buffer. The lower layer was separated then diluted with MeOH (20 mL) and warmed to dissolve the suspended solid. The aqueous phase was extracted with CH₂Cl₂ (2×20 mL). The extracts were combined, washed with water (100 mL), dried (Na₂SO₄), and concentrated to a volume of 20 mL. The concentrate was diluted with MeOH (20 mL) and was concentrated to a volume of 10 mL. The precipitate was removed by filtration and washed with MeOH to give 18a (0.14 g, 66%) as a pale yellow microcrystalline solid: mp>230° C.; ¹H NMR [(CD₃)₂SO] δ 11.50 (d, J=2.1 Hz, 1 H), 10.03 (br as 1 H), 8.76 (dd, J=4.1, 1.3 Hz, 1 H), 8.40 (dd, J=8.4, 1.3 Hz, 1 H), 7.97 (s, 1 H), 7.56 (dd, J=8.4, 4.1 Hz, 1 H), 7.09 (d, J=2.1 Hz, 1 H), 6.97 (s, 1 H), 4.77 (dd, J=11.0, 9.3 Hz, 1 H), 4.48 (dd, J=11.0, 2.0 Hz, 1 H), 4.25 (dddd, J=9.3, 3.9, 3.3, 2.0 Hz, 1 H), 4.03 (dd, J=10.6, 3.3 Hz, 1 H), 3.93, 3.82, 3.80 (3×s, 3 H each), 3.89 (dd, J=10.6, 3.9 Hz, 1 H); ¹³C NMR ((CD₃)₂SO) δ 160.3, 153.9, 146.3, 149.1, 142.7, 139.9, 139.0, 136.0, 130.7, 125.4, 124.8, 123.1, 131.6, 122.4, 114.6, 106.2, 102.8, 98.0, 61.0, 60.9, 55.9, 55.0, 47.6, 40.5. Anal. Calcd for C₂₄H₂₂ClN₃O₅: C, 61.61; H, 4.74; Cl, 7.58; N, 8.98. Found: C, 61.50; H, 4.98; N, 8.84.

[0184] Compound 18a by Method 2.

[0185] A solution of 16 (0.14 g, 0.43 mmol) in dioxane (9 mL) was saturated with HCl, allowed to stand for 1 h, and evaporated. 5,6,7-Trimethoxyindole-2-carboxylic acid (0.11 g, 0.43 mmol), EDCI (0.25 g, 1.28 mmol) and DMA (5 mL) were added to the remaining yellow solid, and the red mixture was stirred at room temperature for 22 h. The mixture was poured into a mixture of ice (20 g) and pH 7.4 phosphate buffer (20 mL). The precipitate was removed by filtration, washed with water, and taken up in CH₂Cl₂—MeOH (2:1, 30 mL). The CH₂Cl₂ was boiled off, the remaining mixture was cooled in ice, and the precipitate was removed by filtration to give 18a (18 mg, 9%) identical to the material prepared above.

[0186] Similarly were prepared:

[0187] 1-(Chloromethyl)-3-({5-[2-(dimethylamino)ethoxyl]-5-hydroxyindol-2-yl}carbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (18b).

[0188] A suspension of 14 (0.20 g, 0.47 mmol) in cooled (0° C.) dioxane (5 mL) was saturated with HCl, allowed to warm to r.t. over 2 h and evaporated. 5-[2-(Dimethylamino)ethoxy]-1-H-indole-2-carboxylic acid hydrochloride (0.13 g, 0.47 mmol) [Milbank et al., J. Med. Chem., 1999, 42, 649], EDCI (0.27 g, 1.42 mmol) and DMA (3 mL) were added to the remaining yellow solid, and the red mixture was stirred at r.t. for 20 h. The mixture was partitioned between EtOAc and 5% NaHCO₃ solution. The aqueous layer was extracted with EtOAc (×3). The EtOAc extracts were dried (brine, Na₂SO₄). Flash chromatography (Alumina, EtOAc/MeOH; 49:1, then 9:1) gave 2-[(2-{[5-1-(benzyloxy)-1-(chloromethyl)-1,2-dihydro-3H-pyrrolo[3,2-f]quinolin-3-yl]carbonyl}-1H-indol-5-yl)oxy]-N,N-dimethylethanamine (17b) (0.22 g, 84%) as a yellow solid: mp 176-179° C.; ¹H NMR [(CD₃)₂SO] δ 11.68 (s, 1 H), 8.79 (dd, J=4.1, 1.5 Hz, 1 H), 8.41 (dd, J=8.6, 1.5 Hz, 1 H), 8.29 (s, 1 H ), 7.56 (m, 3 H), 7.40 (m, 4 H), 7.17 (d, J=2.3 Hz, 1 H ), 7.11 (d, J=1.5 Hz, 1 H), 6.92 (dd, J=9.0, 2.4 Hz, 1 H), 5.32 (s, 2 H), 4.82 (dd, J=10.7, 9.6 Hz, 1 H), 4.58 (dd, J=10.9, 2.1 Hz, 1 H), 4.32 (m, 1 H), 4.05 (t, J=5.7 Hz, 2 H), 4.04 (m, 1 H), 3.93 (dd, J=11.2, 6.9 Hz, 1 H), 2.65 (t, J=5.8 Hz, 2 H), 2.23 (s, 6H); ¹³C NMR [(CD₃)₂SO] δ 160.3, 154.5, 153.0, 147.3, 142.3, 137.4, 136.7, 131.6, 131.3, 130.6,128.4, 127.9, 127.7, 127.4, 125.1, 122.4, 116.2, 116.0, 113.1, 105.5, 103.1, 102.0, 70.0, 66.9, 66.2, 57.8, 54.9, 47.7, 45.5, 40.7.

[0189] THF (8 mL) then HCO₂N₄ (0.23 g, 3.6 mmol) in H₂O (1 mL) were added to cooled (0° C.) mixture of 17b (0.20 g 036 mmol) and 10% Pd/C (0.1 g) under N₂. The mixture was stirred at 0° C. for 14 h, and was then filtered through Celite. The Celite was washed with CH₂Cl₂/H₂O. The aqueous layer was extracted with CH₂Cl₂(×3). The CH₂Cl₂ extracts were dried (brine, Na₂SO₄) and passed through a short plug of silica gel to give 18b (0.16 g, 93%) as a yellow solid: mp 209-215° C.; ¹H NMR [(CD₃)₂SO] δ 11.66 (s, 1 H), 10.02 (bs, 1 H), 8.76 (dd, J=4.1, 1.4, 1 H), 8.41 (dd, J=8.5, 1.3, 1 H), 8.07 (s, 1 H), 7.56 (dd, J=8.5, 4.1, 1 H), 7.40 (d, J=8.9, 1 H), 7.17 (d, J=2.2, 1 H), 7.11 (d, J=1.2, 1 H,) 6.93 (dd, J=8.9, 2.3, 1 H), 4.82 (dd, J=10.7, 9.6, 1 H), 4.57 (dd, J=11.0, 2.1, 1 H), 4.29 (m, 1 H), 4.06 (t, J=5.9, 2 H),4.04 (m, 1H),3.91 (dd, J=11.1, 7.2, 1 H),2.64 (t, J=5.8, 2 H),2.28 (s, 6 H); ¹³C NMR [(CD₃)₂SO] δ 160.3, 153.9, 153.0, 146.4, 142.8, 136.1, 131.6, 130.7, 127.4, 124.8, 124.7, 122.5, 116.0, 114.6, 113.1, 105.5, 103.1, 103.0, 66.1, 57.8, 54.9, 47.7, 45.5, 40.7.

[0190] 1-Chloromethyl)-3-((2E)-3-{4-[2-(dimethylamino)ethoxy]phenyl}-2-propenoyl)-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (18c).

[0191] A suspension of 14 (0.20 g, 0.47 mmol) in cooled (0° C.) dioxane (5 mL) was saturated with HCl, allowed to warm to r.t. over 1 h and evaporated. (E)-4-[2-(Dimethylamino)ethoxy]cinnamic acid hydrochloride (0.13 g, 0.47 mmol) [Atwell et al., J. Med. Chem., 1999, 42, 3400], EDCI (0.27 g, 1.42 mmol) and DMA (3 mL) were added to the remaining yellow solid, and the red mixture was stirred at r.t. for 30 h. The mixture was partitioned between CH₂Cl₂ and 5% NaHCO₃ solution. The aqueous layer was extracted with CH₂Cl₂ (×3). The CH₂Cl₂ extracts were dried (brine, Na₂SO₄). Flash chromatography (Alumina, EtOAc/MeOH; 49:1, then 24:1) gave 2-(4-{(1E)-3-[5-(benzyloxy)-1-(chloromethyl)-1,2-dihydro-3H-pyrrolo[3,2-f]quinolin-3-yl]-3-oxo-1-propenyl}phenoxy)-N,N-dimethylethanamine (17c) (0.18 g, 70%) as a yellow solid: mp 172-175° C.; ¹H NMR [(CD₃)₂SO] δ 8.76 (dd, J=4.1, 1.4, 1 H), 8.47 (bs, 1 H), 8.35 (dd, J=8.5, 1.4, 1 H), 7.76 (d, J=8.7, 2 H), 7.67 (d, J=15.3, 1 H), 7.58 (d, J=7.3, 2 H), 7.54 (dd, J=8.5, 4.1, 1 H), 7.44 (t, J=7.2, 2 H), 7.37 (t, J=7.2, 1 H), 7.08 (d, J=15.3, 1 H), 7.02 (d, J=8.7, 2 H), 5.31 (s, 2 H), 4.55 (dd, J=10.7, 9.5, 1 H), 4.44 (dd, J=10.9, 2.5, 1 H), 4.30 (m, 1 H), 4.11 (t, J=5.8, 2 H), 3.99 (dd, J=11.0, 3.0, 1 H), 3.91 (dd, J=11.2, 7.2, 1 H), 2.64 (t, J=5.7, 2 H), 2.23 (s, 6 H); ¹³C NMR [(CD₃)₂SO] δ 164.1, 160.1, 154.6, 147.1, 142.6, 142.2, 137.2, 136.7, 131.1, 130.1, 128.3, 127.83, 127 78, 127.3, 125.1, 122.3, 116.9, 115.7, 114.7, 101.6, 70.0, 65.9, 57.5, 52.9, 47.8, 45.4, 40.1.

[0192] A solution of 17c (0.56 g, 1.03 mmol) was dissolved in CF₃COOH (15 mL) and refluxed for 48 h. CF₃COOH was evaporated and the residue was partitioned between CH₂Cl₂ and cold 5% NaHCO₃ solution. The aqueous layer was extracted with CH₂Cl₂ (×3). The CH₂Cl₂ extracts were dried (brine, Na₂SO₄). Flash chromatography (CH₂Cl₂/MeOH/NH₃; 95:5:trace) gave 18c (0.16 g, 34%) as a yellow solid: mp 174-180° C.; ¹H NMR [(CD₃)₂SO] δ 9.96 (bs, 1 H), 8.73 (dd, J=4.0, 1.3, 1 H), 8.36 (dd, J=8.4, 1.3, 1 H), 8.18 (bs, 1 H), 7.77 (d, J=8.7, 2 H), 7.66 (d, J=15.2, 1 H), 7.54 (dd, J=8.5, 4.1, 1 H), 7.08 (d, J=15.4, 1 H), 7.02 (d, J=8.7, 2 H), 4.54 (dd, J=10.7, 9.5, 1 H), 4.44 (dd, J=11.0, 2.5, 1 H), 4.28 (m, 1 H), 4.11 (t, J=5.7, 2 H), 4.00 (dd, J=11.1, 3.1, 1 H), 3.88 (dd, J=11.0, 7.4, 1 H), 2.64 (t, J=5.8, 2 H), 2.22 (s, 6 H).

[0193] 1-(Chloromethyl)-3-[(5-methoxyindol-2-yl)carbonyl]-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (18d).

[0194] A suspension of 14 (0.10 g, 0.24 mmol) in dioxane (15 mL) was saturated with HCl, stirred at r.t. for 5 h and evaporated. 5-Methoxy-1-H-indole-2-carboxylic acid (0.054 g, 0.28 mmol), EDCI (0.23 g, 1.17 mmol) and DMA (5 mL) were added to the remaining yellow solid, and the red mixture was stirred at r.t. for 52 h. The mixture was partitioned between CH₂Cl₂ and cold 5% KHCO₃ solution. The aqueous layer was extracted with CH₂Cl₂ (×3). The CH₂Cl₂ extracts were dried (brine, Na₂SO₄). Flash chromatography (EtOAc/petroleum ether, 7:3) gave 5-(benzyloxy)-1-(chloromethyl)-3-[(5-methoxy-1H-indol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (17d) (0.11 g, 98%) as a yellow solid: mp 186-189° C.; ¹H NMR (CDCl₃) δ 9.55 (s, 1 H), 8.88 (dd, J=4.2, 1.7, 1 H), 8.37 (s, 1 H), 7.99 (dd, J=8.3, 1.6, 1 H), 7.56 (d, J=7.3, 2 H), 7.42 (dd, J=8.3, 4.1, 1 H), 7.33 (m, 4 H), 7.10 (d, J=2.3, 1 H), 6.99 (m, 2 H), 5.48 (d, J=12.5, 1 H), 5.42 (d, J=12.6, 1 H), 4.74 (dd, J=10.9, 2.0, 1 H), 4.61 (dd, J=10.6, 8.7, 1 H), 4.05 (m, 1 H), 3.85 (s, 3 H), 3.84 (dd, J=11.2, 4.1, 1 H), 3.45 (dd, J=11.0, 10.5, 1 H); ¹³C NMR (CDCl₃) δ 160.7, 155.4, 154.7, 147.9, 142.4, 138.4, 136.4, 131.4, 130.5, 130.2, 128.6, 128.2, 128.0, 127.7, 125.2, 122.4, 117.0, 115.4, 112.7, 106.2, 102.5, 102.4, 70.9, 55.7, 55.2, 45.9, 42.6.

[0195] THF (6 mL) then HCO₂NH₄ (0.14 g, 2.21 mmol) in H₂O (0.7 mL) were added to cooled (0° C.) mixture of 17d (0.11 g, 0.22 mmol) and 10% Pd/C (0.05 g) under N₂. The mixture was stirred at 0° C. for 5 h, and was then filtered through Celite. The Celite was washed with CH₂Cl₂/H₂O. The aqueous layer was extracted with CH₂Cl₂ (×3). The CH₂Cl₂ extracts were dried (brine, Na₂SO₄) and CH₂Cl₂ evaporated. Precipitation from CH₂Cl₂/MeOH gave 18d (0.077 g, 89%) as a grey solid: mp 224-227° C.; ¹H NMR [(CD₃)₂SO] δ 11.66 (s, 1 H), 10.02 (bs, 1 H), 8.77 (dd, J=4.1, 1.3, 1 H), 8.41 (dd, J=8.4, 1.4, 1 H), 8.07 (s, 1 H), 7.57 (dd, J=8.4, 4.1, 1 H), 7.40 (d, J=9.0, 1 H), 7.16 (d, J=2.4, 1 H), 7.12 (d, J=1.6, 1 H), 6.92 (dd, J=8.9, 2.3, 1 H), 4.82 (dd, J=10.8, 9.4, 1 H), 4.57 (dd, J=11.0, 2.3, 1 H), 4.30 (m, 1 H), 4.04 (dd, J=11.1, 3.3, 1 H), 3.91 (dd; J=11.1, 7.2, 1 H), 3.78 (s, 3 H).

[0196] 1-(Chloromethyl)-3-[(2E)-3-(4-methoxyphenyl)-2-propenoyl]-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (18e).

[0197] A suspension of 16 (0.10 g, 0.30 mmol) in dioxane (5 mL) was saturated with HCl, stirred at r.t. over 5 h and evaporated. 4-Methoxycinnamic acid (predominantly trans) (0.064 g, 0.36 mmol), EDCI (0.29 g, 1.50 mmol) and DMA (3 mL) were added to the remaining yellow solid, and the red mixture was stirred at r.t. for 3 h. The mixture was partitioned between CH₂Cl₂ and cold 5% KHCO₃ solution. The aqueous layer was extracted with CH₂Cl₂ (×3). The CH₂Cl₂ extracts were dried (brine, Na₂SO₄). Flash chromatography (CH₂Cl₂/MeOH; 93:7) followed by recrystallisation (CH₂Cl₂/Et₂O) gave 18e (0.02 g, 17%) as a yellow solid: mp 208-211° C.; ¹H NMR [(CD₃)₂SO] δ 9.96 (bs, 1 H), 8.73 (d, J=3.3, 1 H), 8.35 (d, J=7.7, 1 H), 8.18 (bs, 1 H), 7.78 (d, J=8.7, 2 H), 7.67 (d, J=15.3, 1 H), 7.54 (dd, J=8.5, 4.1, 1 H), 7.08 (d, J=15.4, 1 H), 7.01 (d, J=8.7, 2 H), 4.54 (dd, J=10.3, 9.5, 1 H), 4.45 (m, 1 H), 4.27 (m, 1 H), 3.99 (dd, J=11.1, 3.2, 1 H), 3.88 (dd, J=11.1, 7.3, 1 H), 3.82 (s, 3 H). C₂₂H₂₀ClN₂O₃ requires M+H 395.1163, 397.1133. Found (FAB) 395.1161, 397.1169.

[0198] 1-(Chloromethyl)-3-[(2E)-3-(3-hydroxy-4methoxyphenyl)-2-propenoyl]-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (18f).

[0199] A suspension of 16 (0.10 g, 0.30 mmol) in dioxane (5 mL) was saturated with HCl, stirred at r.t. over 5 h and evaporated. 3-Hydroxy-4-methoxycinnamic acid (predominantly trans) (0.070 g, 0.36 mmol), EDCI (0.29 g, 1.50 mmol) and DMA (3 mL) were added to the remaining yellow solid, and the red mixture was stirred at r.t. for 3 h. The mixture was partitioned between CH₂Cl₂ and cold 5% KHCO₃ solution. The aqueous layer was extracted with CH₂Cl₂ (×3). The CH₂Cl₂ extracts were dried (brine, Na₂SO₄). Flash chromatography (CH₂Cl₂/MeOH; 93:7) followed by recrystallisation (CH₂Cl₂/Et₂O) gave 18f (0.01 g, 8%) as a yellow solid: mp 215-218° C.; ¹H NMR [(CD₃)₂SO] δ 9.96 (bs, 1 H), 9.13 (s, 1 H), 8.73 (dd, J=4.1, 1.4, 1 H), 8.36 (dd, J=8.5, 1.4, 1 H), 8.17 (bs, 1 H), 7.57 (d, J=15.3, 1 H), 7.54 (dd, J=8.5, 4.1, 1 H), 7.25 (d, J=2.0, 1 H), 7.20 (dd, J=8.4, 2.0, 1 H), 6.99 (d, J=8.1, 1 H), 6.96 (d, J=15.0, 1 H), 4.54 (dd, J=10.5, 9.4, 1 H), 4.44 (dd, J=11.1, 2.6, 1 H), 4.00 (dd, J=11.2, 3.3, 1 H),3.88 (dd, J=11.1, 7.5, 1 H), 3.83 (s, 3H). C₂₂H₁₉ ³⁵ClN₂O₄ requires M+H 411.1112. Found (FAB) 411.1127.

Example B Preparation of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline 27 by the Method of Scheme 4.

[0200] 8-Nitroquinoline-6-carboxylic Acid (19).

[0201] This was prepared by the reported method [Jung et al., Eur. Pat. Appln. EP 581500 (1994); Chem Abstr, 1994, 122, 205125] in 41% yield: mp (EtOAc) 258-263° C.; ¹H NMR [(CD₃)₂SO] δ 13.80 (v br, 1 H), 9.16 (dd, J=4.3, 1.7 Hz, 1 H), 8.96 (d, J=1.7 Hz, 1 H), 8.80 (dd, J=8.4, 1.6 Hz, 1 H), 8.63 (d, J=1.7 Hz, 1 H), 7.84 (dd, J=8.4, 4.2 Hz, 1 H).

[0202] 6-(tert.-Butyloxycarbonylamino)-8-nitroquinoline (20)

[0203] A mixture of 19 (4.82 g, 22.1 mmol), DPPA (6.99 g, 25.4 mmol) and Et₃N (3.69 mL, 26.5 mmol) in anhydrous t-BuOH (60 mL) was heated at reflux under N₂ for 8 h. The mixture was concentrated under reduced pressure, and the residue was partitioned between CH₂Cl₂ and 10% aqueous KHCO₃. The organic phase was washed with 10% aqueous KHCO₃, dried (Na₂SO₄) and concentrated under reduced pressure, then chromatographed on silica gel. Elution with CH₂Cl₂/EtOAc (17:3), followed by sequential crystallisation from MeOH/H₂O and CH₂Cl₂/petroleum ether gave 20 (3.82 g, 60%): mp 134-135° C.; ¹H NMR [(CD₃)₂SO] δ 10.09 (s, 1 H), 8.87 (dd, J=4.1, 1.5 Hz, 1 H), 8.47 (dd, J=8.5, 1.6 Hz, 1 H), 8.33 (d, J=1.9 Hz, 1 H), 8.25 (d, J=2.2 Hz, 1 H), 7.65 ,m(dd, J=2.2 Hz, 1 H), 7.65 (dd, J=8.5, 4.2 Hz, 1 H), 1.53 (s, 9 H). Anal. Calcd. for C₁₄H₁₅N₃O₄: C, 58.12; H, 5.23; N, 14.53. Found: C, 58.39; H, 5.21; N, 14.65%.

[0204] 8-Amino-6-(tert.-butyloxycarbonylamino)quinoline (21)

[0205] A solution of 20 (3.30 g, 11.4 mmol) in MeOH (50 mL) was hydrogenated over 10% Pd/C at 50 psi for 3 h. The resulting crude product was filtered through a column of silica gel in EtOPAc to give 21 (2.71 g, 92%): mp (i-Pr₂O/petroleum ether) 131-132° C.; ¹H NMR [(CD₃)₂SO] δ 9.39 (s, 1 H), 8.54 (dd, J=4.1, 1.6 Hz, 1 H), 8.01 (dd, J=8.3, 1.5 Hz, 1 H), 7.36 (dd, J=8.3, 4.1 Hz, 1 H), 7.24 (d, J=2.0 Hz, 1 H), 6.97 (d, J=2.1 Hz, 1 H), 5.90, 5.88 (2×s, 2 H, NH₂), 1.50 (s, 9 H). Anal. Calcd. for C₁₄H₁₇N₃O₂: C, 64.85; H, 6.61; N, 16.20. Found: C, 64.60; H, 6.77; N, 16.19%.

[0206] 6-(tert.-Butyloxycarbonyl)-8-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)quinoline (22).

[0207] A mixture of 21 (1.53 g, 5.90 mmol), phthalic anhydride (1.05 g, 7.09 mmol) and DMAP (36 mg, 5 mol %), in anhydrous pyridine (15 mL) was heated with stirring at 80° C. for 1 h. The mixture was concentrated under reduced pressure, then AcOH (10 mL) and Ac₂O (5 ml) were added and the mixture was stirred at 80° C. for a further 45 min. Concentration under reduced pressure, followed by addition of aqueous KHCO₃, gave a solid that was chromatographed on silica gel. Elution with CH₂Cl₂/EtOAc (4:1) gave a crude product that was crystallized from CH₂Cl₂/iPr₂O to give 22 (2.09 g): mp 217-218° C. (dec.); ¹H NMR [(CD₃)₂SO] δ 10.00 (s, 1 H), 8.67 (d, J=3.2 Hz, 1 H), 8.39 (d, J=8.1 Hz, 1 H, H-4), 8.24 (s, 1 H), 8.80-7.89 (m, 5 H), 7.53 (dd, J=8.3, 4.1 Hz, 1 H), 1.53 (s, 9 H). Anal. Calcd. for C₂₂H₁₉N₃O₄: C, 67.85; H, 4.92; N, 10.79. Found: C, 67.87; H, 4.94; N, 10.87%.

[0208] 5-Bromo-6-(teyt.-butyloxycarbonylamino)-8-(1,3-dioxo-1,3-dihydro-1H-isoindol-2-yl)quinoline (23).

[0209] A mixture of 22 (1.79 g, 4.6 mmol) and NBS (0.98 g, 5.5 mmol) in anhydrous CH₃CN (50 mL) was stirred at reflux for 45 min, then concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂, and the solution was washed with aqueous Na₂S₂O₅/NaHCO₃ and water (2×), dried (Na₂SO₄) and concentrated to dryness. The residue was chromatographed on silica gel, and elution with CH₂Cl₂/EtOAc (3:2) gave a crude product that was crystallized from EtOAc/iPr₂O to 23 (1.91 g, 89%): mp 210-211° C. (dec.); ¹H NMR [(CD₃)₂SO] δ 9.19 (s, 1 H), 8.85 (dd, J=4.1, 1.4 Hz, 1 H), 8.65 (dd, J=8.6, 1.4 Hz, 1 H), 8.21 (s, 1 H), 8.07-7.92 (m, 4 H), 7.75 (dd, J=9.7, 4.2 Hz, 1 H), 1.50 (s, 9 H). Anal. Calcd. for C₂₂H₁₈BrN₃O₄: C, 56.42; H, 3.87; N, 8.98; Br, 17.06. Found: C, 56.49; H, 4.04; N, 8.86; Br, 16.87%.

[0210] 5-Bromo-6-[N-(tert.-butyloxycarbonyl)-N-(3-chloro-2-propen-1-yl)amino]-8-(1,3-dioxo-1,3-dihydro-1H-isoindol-2-yl)quinotine (24).

[0211] A solution of 23 (1.82 g, 3.89 mmol) in anhydrous DMF (20 mL) was treated at 0° C. under N₂ with NaH (0.20 g, 5.00 mmol, 60% in oil), and then stirred at 25° C. for 45 min. The mixture was then cooled to 0° C. and 1,3-dichloropropene (1.11 mL, 11.7 mmol) was added. The reaction mixture was warmed to 25° C., stirred for 4 h, and then diluted with CH₂Cl₂ (200 mL). The solution was washed with 10% aqueous KHCO₃ and water (2×), then dried (Na₂SO₄) and concentrated under high vacuum at 25° C. The residue was chromatographed on silica gel, eluting with CH₂Cl₂ then CH₂Cl₂/EtOAc (17:3) to give 24 (1.62 g, 77%) as a foam that was used directly; ¹H NMR [(CD₃)₂SO] (mixture of rotamers of E and Z alkenes) δ 8.94 (d, J=4.0 Hz, 1 H), 8.73 (d, J=8.6 Hz, 1 H), 8.12-7.93 (m, 5 H), 7.80 (dd, J=8.6, 4.2 Hz, 1 H), 6.50-6.35 (m, 1 H), 6.21-6.02 (m, 1 H), 4.62-4.06 (m, 2 H), 1.51, 1.32 (2×s, 9 H). Anal. Calcd. for C₂₅H₂₁BrClN₃O₄.2H₂O: C, 51.87; H, 4.35; N, 7.26. Found: C, 51.69; H, 3.87; N, 6.86%.

[0212] 3-(tert.-Butyloxycarbonyl)-1-(chloromethyl)-5-(1,3-dioxo-1,3-dihydro-1H-isoindol-2-yl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (25).

[0213] A mixture of 24 (1.96 g, 3.61 mmol) and catalytic AIBN (60 mg, 10 mol %) in anhydrous benzene (20 mL) was treated with Bu₃SnH (1.16 mL, 4.33 mmol) and heated at reflux under N₂ for 3 h The reaction mixture was concentrated under reduced pressure and the residue was chromatographed on silica gel. Elution with CH₂Cl₂/EtOAc (17:3), followed by crystallisation from CH₂Cl₂/petroleum ether gave 25 (1.28 g, 76%): mp 163-165° C.; ¹H NMR [(CD₃)₂SO] δ 8.70 (dd, J=4.1, 1.3 Hz, 1 H), 8.51 (dd, J=8.6, 1.4 Hz, 1 H), 8.45 (v br, 1 H), 8.06-7.90 (m, 4 H), 7.57 (dd, J=8.5, 4.1 Hz, 1 H), 4.44-4.34 (m, 1 H), 4.29 (t, J=10.5 Hz, 1 H), 4.19-3.99 (m, 3 H), 1.54 (s, 9 H). Anal. Calcd. for C₂₅H₂₂ClN₃O₄: C, 64.72; H, 4.78; N, 9.06. Found: C, 64.76; H, 4.92; N, 9.03%.

[0214] 1-(Chloromethyl)-5-(1,3-dioxo-1,3-dihydro-1H-isoindol-2-yl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (26).

[0215] A solution of 25 (500 mg, 108 mmol) in dioxane at 10° C. was saturated with HCl gas, allowed to stand at 20° C. for 1 h, then evaporated to dryness under reduced pressure below 30° C. 5,6,7-Trimethoxyindole-2-carboxylic acid (298 mg, 1.19 mmol), EDCI (518 mg, 2.70 mmol) and anhydrous DMA (10 mL) were then added, and the mixture was stirred at 20° C. for 3 h Addition of 10% aqueous KHCO₃ precipitated a solid that was chromatographed on silica gel. Elution with CH₂Cl₂/EtOAc (1:1), followed by crystallisation from EtOAc/iPr₂O, gave 1-(chloromethyl)-5-(phthalimido)-3-[(5,6,7-triethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline 26 (392 mg, 6 1%): mp 189-191° C.; ¹H NMR [(CD₃)₂SO] δ 11.54 (s, 1 H), 8.77 (dd, J=4.1, 1.4 Hz, 1 H), 8.75 (s, 1 H), 8.59 (dd, J=8.5, 1.4 Hz, 1 H), 8.08-7.92 (m, 4 H), 7.61 (dd, J=8.5, 4.2 Hz, 1 H), 7.14 (d, J=1.7 Hz, 1 H), 6.98 (s, 1 H), 4.89 (dd, J=10.8, 9.7 Hz, 1 H), 4.61 (dd, J=11.0, 2.3 Hz, 1 H), 4.55-4.44 (m, 1 H), 4.20-4.05 (m, 2 H), 3.94, 3.83, 3.81 (3×s, 3×3H). Anal. Calcd. for C₃₂H₂₅ClN₄O₆: C, 64.37; H, 4.22; N, 9.39. Found: C, 64.04; H, 4.28; N, 9.29%.

[0216] 5-Amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (27).

[0217] A solution of 26 (160 mg, 0.27 mmol) in CH₂Cl₂ (6 mL) was was diluted with EtOAc (8 mL) and treated immediately with hydrazine monohydrate (155 μL, 3.19 mmol). The reaction mixture was stirred at 25° C. for 2 h, then diluted with CH₂Cl₂ (40 mL), washed with 10% aqueous Na₂CO₃ (2×) and saturated aqueous NaCl (2×), dried (Na₂SO₄) and concentrated under reduced pressure below 30° C. Chromatography on silica gel, eluting with CH₂Cl₁/EtOAc (1:1) gave 27 (81 mg, 65%): mp 225-227° C.; ¹H NMR [(CD₃)₂SO] δ 11.44 (s, 1 H), 8.63 (dd, J=4.1, 1.4 Hz, 1 H), 8.25 (dd, J=8.5, 1.4 Hz, 1 H), 7.82 (s, 1 H), 7.47 (dd, J=8.5, 4.1 Hz, 1 H), 7.05 (d, J=1.2 Hz, 1 H), 6.99 (s, 1 H), 6.18, 6.16 (2×s, 2 H), 4.70 (dd, J=10.8, 9.1 Hz, 1 H), 4.43 (dd, J=11.0, 1.8 Hz, 1 H), 4.16-4.08 (m, 1 H), 3.97 (dd, J=11.0, 3.3 Hz, 1 H), 3.94, 3.82, 3.80 (3×s, 3×3 H), 3.76 (dd, J=10.0, 7.8 Hz, 1 H). Anal. Calcd. for C₂₄H₂₃ClN₄O₄: C, 61.74; H, 4.96; N, 12.00. Found: C, 61.51; H, 5.04; N, 11.69%.

Example C Preparation of 5-(2-aminoethylamino)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indole Dihydrochloride 29 by the Method of Scheme 5

[0218] A mixture of 5-amino-1-(chloromethyl)-3-[5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole 28 [Atwell et al., J. Org. Chem. 1998, 63, 9414] (252 mg, 0.54 mmol), N-(tert-butyloxycarbonyl)aminoacetaldehyde (430 mg, 2.70 mmol) TsOH (10 mg) and microwave-dried powdered A4 molecular sieves (3 g) in DMA (3 mL) and MeOH (0.5 mL) was stirred at 20° C. under N₂ with the exclusion of light for 48 h. NaBH₃CN (170 mg, 2.70 mmol) was added and the mixture was stirred for a further 4 h at 20° C., then poured into water. After prolonged cooling the resulting oily precipitate was collected and extracted with CH₂Cl₂. Following filtration the solution was washed with water, dried (Na₂SO₄) and then concentrated under reduced pressure below 30° C. The residue was chromatographed on silica gel, eluting with CH₂Cl₂/EtOAc (9:2), to provide material that was precipitated from a CH₂Cl₂ solution with petroleum ether at 20° C. to give 5-[2-(tert-butyloxycarbonylamino)ethylamino]-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (132 mg, 40%), mp 110-115° C. ¹H NMR [(CD₃)₂SO] δ 11.45 (s, 1 H), 8.09 (d, J=8.5 Hz, 1 H), 7.79 (d, J=8.3 Hz, 1 H), 7.53-7.26 (underlying v br s, 1 H), 7.49 (t, J=7.7 Hz, 1 H), 7.33 (t, J=7.6 Hz, 1 H), 7.04 (s, 1 H), ca 7.07-7.00 (obscured signal, 1 H), 6.97 (s, 1 H), 6.28 (br s, 1 H), 4.68 (t, J=9.8 Hz, 1 H), 4.45 (dd, J=11.0, 1.4 Hz, 1 H), 4.17-4.07 (m, 1 H), 3.98 (dd, J=11.0, 3.0 Hz, 1 H), 3.92 (s, 3 H), 3.82 (s, 3 H), 3.80 (s, 3 H), 3.76 (dd, J=10.7, 8.0 Hz, 1 H), ca 3.3 (br s, obscured by H₂O signal but visible after D₂O exchange, 2 H), 3.18 (br s, 2 H), 1.39 (s, 9 H). Anal. Calcd. for C₃₂H₃₇ClN₄O₆: C, 63.1; H, 6.1; N, 9.2; Cl, 5.8. Found: C, 63.0; H, 6.1; N, 9.4; Cl, 5.7%.

[0219] A solution of the above compound (122 mg, 0.20 mmol) in dioxane (3 mL) was treated with HCl-saturated EtOAc (3 mL), and the mixture was stood at 20° C. for 1 h. Excess EtOAc was then added to complete separation of the product, which was collected and recrystalised from MeOH/EtOAc/petroleum ether/HCl to give 5-(2-aminoethylamino)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indole dihydrochloride 29 (86 mg, 74%), mp>200° C. ¹H NMR [free base in (CD₃)SO] δ 11.46 (br s, 1 H), 8.17 (d, J=8.6 Hz, 1 H), 7.78 (d, J=8.2 Hz, 1 H), ca. 7.5-7.3 (underlying v br s, 1 H), 7.49 (t, J=7.6 Hz, 1 H), 7.32 (t, J=7.7 Hz, 1 H), 7.04 (s, 1 H), 6.97 (s, I H), 6.28 (t, J=5.0 Hz, 1 H), 4.67 (t, J=9.5 Hz, 1 H), 4.45 (dd, J=11.0, 1.3 Hz, 1 H), 4.19-4.07 (m, 1 H), 3.98 (dd, J=10.9, 3.0 Hz, 1 H), 3.92 (s, 3 H), 3.82 (s, 3 H), 3.80 (s, 3 H), 3.77 (dd, J=11.0, 8.2 Hz, 1 H), 3.12 (br s, 2 H), 2.84 (br s, 2 H). Anal. Calcd. for C₂₇H₂₉ClN₄O₄.2HCl.0.5H₂O: C, 54.9; H, 5.5; N, 9.5. Found: C, 55.1; H, 5.5; N, 9.1%.

Example D Preparation of Ancillary Ligands

[0220] 1,4,7,10-Tetraazacyclododecane-1,7-dipropanesulfonic Acid Tetrahydrochloride (32).

[0221] A solution of perhydro-3,6,9,12-tetraazacyclopenteno[1,3-f,g]acenaphthylene (30) (0.50 g, 2.58 mmol) [Weisman et al., Tetrahedron Lett., 21, 1980, 335] and 1,3-propanesultone (1.57 g, 12.9 mmol) in CH₃CN (20 mL) was stirred at 80° C. under N₂ for 72 h. The suspension was cooled to room temperature and the white precipitate was filtered and washed with excess CH₃CN to give 1,7-bis(3-sulfopropyl)-4,10-diaza-1,7-diazoniatetracyclo[5.5.2.0.^(4,14)0^(10,13)]tetradecane (31) (0.98 g, 86%): mp 279-281° C.; ¹H NMR (D₂O) δ 4.49 (s, 2 H), 3.95 (m, 8 H), 3.82 (bd, J=13.3, 2 H), 3.60 (m, 4 H), 3.38 (bd, J=14.0, 2 H), 3.05 (m, 8 H), 239 (m, 2 H), 2.27 (m, 2 H); ¹³C NMR D₂O) δ 81.6, 64.2, 58.7, 57.6, 49.8, 49.0, 45.3, 21.4. C₁₆H₃₀N₄O₆S₂ requires M+H 439.1685. Found (FAB) 439.1686.

[0222] A mixture of 31 (0.50 g, 1.14 mmol) and hydrazine monohydrate (15 mL, 98%) were heated (100° C.) under N₂ for 48 h. Excess hydrazine was removed and the residue was dissolved in H₂O. Acidification with HCl gave a yellow solution. Evaporation of H₂O gave a brown solid (hygroscopic). Trituration with MeOH (×10) gave 32 (0.59 g, 91%) as a cream powder: mp 322-325° C.; ¹H NMR (D₂O) δ 3.24 (m, 8 H), 2.94 (m, 12 H), 2.82 (m, 4 H), 1.95 (quintet, J=7.4, 4 H); ¹³C NMR (D₂O) δ 53.9, 51.7, 49.9, 45.1, 21.7.

[0223] 1,4,7,10-Tetraazacyclododecane-1-butanesulfonic Acid Tetrahydrochloride (34).

[0224] A solution of 30 (0.50 g, 2.58 mmol) and 1,4-butanesulfone (1.75 g, 12.9 mmol) in CH₃CN (15 mL) was stirred at 60° C. under N₂ for 48 h. The suspension was cooled to room temperature and the white precipitate was filtered and washed with excess CH₃CN to give 4-decahydro-4a,6a,8a-triaza-2a-azoniacyclopenta[f,g]acenaphthylen-2a-yl-1-butanesulfonate (33) (0.82 g, 96%): mp 301-303° C.; ¹H NMR (D₂O) δ 3.91 (m, 1 H), 3.91 (d, J=2.5, 1 H), 3.80 (m 3 H), 3.67 (m, 1 H), 3.58 (d, J=2.7, 1 H), 3.53 (m, 1 H), 3.43 (m, 1 H), 3.24 (m, 4 H), 3.00 (t, J=7.3, 2 H), 2.87 (m, 5 H), 2.50 (m, 2 H), 2.09(m, 1 H), 1.98(m, 1 H), 1.85 (m, 2 H); ¹³C NMR (D₂O) δ 86.5, 74.4, 64.8, 60.4, 59.6, 53.9, 52.5, 51.1, 50.9, 50.4, 50.3, 46.3, 24.2, 24.0. C₁₄H₂₆N₂O₄S requires M+H 331.1804. Found (FAB) 331.1806.

[0225] A mixture of 33 (0.30 g, 0.92 mmol) and hydrazine monohydrate (6 mL, 98%) was heated (80° C.) under N₂ for 36 h. Excess hydrazine was removed and the residue was dissolved in H₂O. Acidification with HCl gave a yellow solution. Evaporation of H₂O gave a brown solid (hygroscopic). Trituration with MeOH (×10) gave 34 (0.41 g, 97%) as a cream powder: mp 322-325° C.; ¹H NMR (D₂O) δ 3.20 (m, 16 H),2.95 (m, 4 H), 1.78 (m, 4 H); ¹³C NMR (D₂O) δ 56.2, 52.9, 52.1, 51.6, 46.4, 45.5, 44.9, 25.1, 24.4.

[0226] 1,4,7,10-Tetraazacyclododecane-1,7-dipentanoic Acid (36).

[0227] A solution of 30 (0.10 g, 0.52 mmol) and ethyl 4-iodobutyrate (0.79 g, 3.09 mmol) [Nudelman et al., Bioorg. Chem., 26, 1998, 157] in CH₃CN (5 mL) was stirred at 60° C. under N₂ for 6 days. A further portion of the iodide (0.26 g, 1.03 mmol) was added and the reaction was stirred at 60° C. under N₂ for 3 weeks. CH₃CN was removed and the residue was partitioned between CH₂Cl₂ and H₂O. The aqueous layer was extracted with CH₂Cl₂ (×6). H₂O was evaporated and the residue was solidified with CH₃CN/Et₂O followed by trituration with Et₂O (×4) to give 1,7-bis(ethoxycarbonylbutyl)-4,10-diaza-1,7-diazoniatetracyclo[5.5.2.0.^(4,14)0^(10,13)]tetradecane diiodide (35) (0.32 g, 87%): ¹H NMR (D₂O) δ 4.46 (s, 2 H), 4.17 (q, J=7.2, 4 H), 3.92 (m, 6 H), 3.77 (m, 4 H), 3.59 (m, 2 H), 3.45 (td, J=12.8, 4.1, 2 H), 3.35 (bd, J=13.9, 2 H), 3.06 (m, 4 H), 2.48 (t, J=7.3, 4 H), 1.96 (m, 2 H), 1.85 (m, 2 H), 1.69 (quintet, J=7.3, 4 H), 1.25 (t, J=7.2, 6 H); ¹³C NMR (D₂O) δ 178.6, 81.2, 64.5, 64.4, 60.2, 57.9, 49.0, 45.3, 35.9, 24.8, 23.8, 16.1. C₂₄H₄₄I₂N₄O₄ requires M+H−I 579.2407. Found (FAB) 579.2410.

[0228] A mixture of 35 (0.05 g, 0.08 mmol) and 15% aqueous KOH (5 mL) was stirred at 70° C. under N₂ for 48 h. Water was evaporated and the residue was acidified to pH 2.5 with HCl. The mixture was loaded onto a DOWEX 50W-X8 cation exchange resin (H⁺form). Elution with H₂O followed by 0.5M NH₃ gave 36 (0.03 g, 100%) as a colourless oil: ¹H NMR (D₂O) δ 2.86 (m, 8 H), 2.68 (m, 8H), 2.53 (t, J=7.4, 4 H), 2.20 (q, J=7.0, 4 H), 1.55 (m, 4 H), 1.47 (m, 4 H); ¹³C NMR (D₂O) δ 183.1, 53.1, 49.1, 42.8, 37.1, 24.1, 23.8. C₁₈H₃₆N₄O₄ requires M+H 373.2815. Found (FAB) 373.2810.

Example E Preparation of Metal Complexes

[0229] Preparation of Complex M1 of Table 1. [[Co(cyclen)18a)](ClO₄)₂].

[0230] [Co(cyclen)(NO₂)₂](NO₂) (38) [Collman and Schneider, Inorg. Chem. 1966, 5, 1380] (1.03 g, 2.79 mmol) was cautiously added with stirring to neat triflic acid (10 mL) cooled in an ice bath The solution was bubbled with N₂ to remove NO_(x) gas and warmed briefly at 40-50° C. until reaction was complete. Dry Et₂O (250 mL was added slowly to the above cold solution (ice-bath) with vigorous stirring, and the resulting precipitate was filtered off, washed (4× dry Et₂O) and dried in a desiccator to give [Co(cyclen)(OTf)₂](OTf) (39) (1.95 g, 100%). Anal. Calcd. for C₁₁H₂₄CoF₉N₄O₁₁S₃: C, 18.49; H, 3.39; N, 7.85. Found: C, 18.43; H, 3.49; N, 7.84. HRMS FAB⁺ [M-OTf]⁺ calculated for: C₁₀H₂₀CoF₆N₄O₆S₂=529.00605. Found: 529.00406. (39) (90 mg, 0.132 mmol) was dissolved in dry CH₃CN (3 mL) and 18a (62 mg, 0.132 mmol) was added. To the stirred solution was added iPr₂NEt (25 mg, 1.5 equiv). This resulted in rapid darkening of the solution to a brown colour but with significant amounts of suspended yellow solid (unreacted/undissolved) 18a present. The mixture was stirred at room temperature for 11 days, during which time nearly all of the suspended solid disappeared. The small amount remaining was removed by filtration through a 0.45μ membrane filter and the filtrate made slightly acidic with dilute aqueous HClO₄. Excess 1 M NaClO₄ (aq) was added and the solution was extracted 4× with 5 mL CH₃NO₂. The combined extracts were evaporated to dryness, the residue resuspended in dry Et₂O (15 mL) and again evaporated to dryness (first on a Rotovapor, finally on a vacuum line) below 20° C., to give crude product as brown flakes of glassy material (103 mg, 86%). HRMS FAB [M-ClO₄]⁺. This material was further purified on reverse-phase HPLC, and the pooled pure fractions were concentrated under reduced pressure, then combined with excess aqueous 1 M NaClO₄ and extracted 5× with CH₂Cl₂. The combined organic extracts were treated as above to give complex M1 as brownish flakes (˜70 mg). HRMS FAB [M-2ClO₄—H]⁺ Calcd for C₃₂H₄₁ ³⁵ClCoN₇O₅; 697.21897. Found, 697.21327. Calcd for C₃₂H₄₁ ³⁷ClCoN₇O₅; 699.21602. Found, 699.21601.

[0231] Preparation of Complex M2 of Table 1. [[Co(cyclen)(18c)](ClO₄)₂]

[0232] [Co(cyclen)(OTf)₂](OTf) (39) (0.087 g, 0.128 mmol) was dissolved in dry CH₃CN (4 mL) and 18c (0.052 g, 0.115 mmol) was added. The mixture was stirred at room temperature for 8 h then cooled overnight at 5° C. A small amount of unreacted 18c was removed by filtration and the bright yellow solid washed with cold CH₃CN and the washes added to the filtrate. This dark brown solution was reduced to ca. 2 mL by evaporation of solvent under reduced pressure at room temperature and then chromatographed on a short (3.3×40 mm) flash silica gel column (0.32-0.60 μm). Elution started with MeOH(CH₃NO₂ (5%) which was stepwise enriched with MeOH up to 15%. At this concentration the main band was eluted first followed closely by a small yellow brown band. A stationary red band remains at the top of the column. Removal of the solvent on a rotary evaporator then on a vacuum line to give M2 as a brown glassy residue (0.089 g, 79%). HRMS FAB⁺ [M-2OTf]⁺ Calcd. for C₃₃H₄₅ ³⁵ClCoN₇O₃ 681.26044. Found, 681.26064; for ³⁷Cl=683.25749. Found, 683.26086.

[0233] Preparation of Complex M3 of Table 1. [[Co(cyclen)(18b)](ClO₄)₂]

[0234] This was prepared as above from 39 (0.101 g, 0.149 mmol) and 18b (0.055 g, 0.118 mmol) to give, after flash chromatography on silica gel, M3 (0.078 g, 67%). HRMS FAB⁺ [M-2OTf]⁺ calculated for C₃₃H₄₄ ³⁵ClCoN₈O₃ 694.25569. Found=694.25305; for ³⁷Cl=696.25274. Found=696.25401.

[0235] Preparation of Complex M4 of Table 1. [Cr(acac)₂(18a)].

[0236] Solid 18a (20 mg, 0.0427 mmol) was added to a solution of [Cr(acac)₂(H₂O)₂]ClO₄.2H₂O (mixture of cis and trans isomers; Ogino, et al., Inorg. Chem. 1988, 27, 986) (0.03 g, 0.071 mmol) in dry CH₃CN (3 mL). The mixture was stirred and a solution of iPr₂NEt (6 mg, 0.0464 mmol) in CH₃CN (0.5 mL) was added gradually over 1 h. The solution was warmed in an oil bath at 50° C. for 0.5 h, then stirred at ambient temperature for 2 weeks. During this period undissolved 18a gradually disappeared as the complexation reaction proceeded giving a clear red-brown solution. The solvent was removed under reduced pressure and the residue was dissolved in CHCl₃ (1.0 mL) and purified by flash chromatography on silica gel. Elution with a CH₃CN/CHCl₃ gradient from 0 to 50% CH₃CN eluted a single yellow-brown band that trailed somewhat near the bottom of the column. The trailing material was eluted separately with 100% CH₃CN. A small amount of green irreversibly absorbed material was left at the top. The main band and tailing fraction were evaporated to dryness under reduced pressure to give yellow-brown powders of Cr(acac)₂(18a) (18 mg, 59% ) and (5 mg, 16%), respectively.

[0237] These two samples gave identical accurate mass spectral results; approximately equal amounts of both [M]⁺ and [M+H]⁺ ions observed with relative intensities consistent with one ³⁵Cl or ³⁷Cl per molecule. FAB⁺-MS: [M]⁺ calc. for C₃₄H₃₅Cl⁵²CrN₃O₉=716.14669. Found, [M]⁺=716.14642. [M+H]⁺ calc. for C₃₄H₃₆ ³⁷Cl⁵²CrN₃O₉=719.15157. Found, [M+H]⁺=719.15122. Fragments corresponding to loss of acac ligand are observed, and the base peak corresponds to Cr(acac)₂. Analytical HPLC on an RP C-18 column using gradient elution starting from a 1:1 (v/v) mixture of 80% aqueous CH₃CN and phosphate buffer (pH=7.4, 0.04 M) showed one major peak (96.7%) with a prominent UV absorption band at 339 nm. A small amount (0.45%) of uncomplexed 2 could be detected and its identity was confirmed by spiking. Because of the paramagnetic properties of the Cr(III) present in this complex, ¹H or ¹³C resonances were not observed by NMR.

[0238] Preparation of Complex M5 of Table 1. [Co(Me₂dtc)₂(18a)]

[0239] [Co₂(Me₂dtc)₅]BF₄ (105 mg, 0.1303 mmol) [Hendrickson et al., J. Chem. Soc. Dalton Trans. 1975, 2182] was added to a suspension of 18a (46 mg, 0.0983 mmol) in 5% MeOH/CH₂Cl₂ (4 mL). iPr₂NEt (25 mg, 2 equiv) was added to stirred suspension in two portions with the second added one day after the first Stirring was continued at room temperature for 8 days, by which time very little suspended/unreacted 18a was evident, and the colour of the solution was the deep green of the co-product Co(Me₂dtc)₃. The solution was filtered and the filtrate evaporated under reduced pressure. The residue was taken up in CH₂Cl₂ (2 mL) and chromatographed on a flash silica gel column. Elution began in CH₂Cl₂, and a large green band of Co(Me₂dtc)₃ was eluted. Stepwise enrichment with CH₃CN in increments of 10% was carried out until the product —[Co(Me₂dtc)₂(18a)] (M5) was eluted (with ca 50% CH₃CN/CH₂Cl₂). The main muddy yellow-green band was collected, and solvent was removed under reduced pressure to give the product as a brownish-green amorphous residue (48 mg, 63%). Analytical reverse-phase HPLC indicated no detectable free cyrotoxic ligand 18a present.

[0240] Preparation of Complex M6 of Table 1. [[Cr(acac)₂(29)]ClO₄)]

[0241] A suspension of 29 (31 mg, 0.058 mmol) in CH₃OH (0.5 mL) was treated with a solution of NaOH (5 mg, 0.119 mmol) dissolved in CH₃OH (0.5 mL), and the neutralised solution was immediately added to a another containing a mixture of cis- and trans-[Cr(acac)₂(OH₂)₂]ClO₄.2H₂O (29 mg, 0.069 mmol) dissolved in CH₃CN (1.0 mL). The combined mixture was stirred at 50° C. for 15 min, cooled to room temperature and the solvent removed under reduced pressure. Chromatography on silica gel gave [Cr(acac)₂(29)]ClO₄ (M6) as a purple residue after drying under vacuum over silica gel desiccant. HRMS (FAB⁺/NBA): Calculated [M⁺] for C₃₇H₄₃N₄ ³⁵ClCrO₈, 758.21834. Found, 758.21745.

[0242] Preparation of Complex M7 of Table 1 [[Co(TACN)(8-HQ)(CN)]ClO₄]

[0243] Co(TACN)(NO₂)₃ was prepared from Na₃[Co(NO₂)₆], using the method of Wieghardt et al., Chem. Ber., 1979, 112, 2220-2230. This was then used to prepare [Co(TACN)(H₂O)₃](OTf)₃ (91% yield), essentially by the method of Galsboel et al., Acta Chem. Scand., 1996, 50, 567-570. [Co(TACN)(H₂O)₃](OTf)₃ (360 mg, 0.509 mmol) was dissolved in EtOH (9 mL) and 8-hydroxyquinoline (8-HQ) (73 mg, 0.6 mmol) added as a solid. Immediately a solution of Et₃N (62 mg) in EtOH (˜4 mL) was added to the stirred solution, which was then warmed briefly to complete the coordination of 8-HQ to the cobalt centre. NaCN (150 mg, 4 equiv) was added portionwise, and the mixture was stirred for 24 hours. During the addition of NaCN and occasionally thereafter, the pH was adjusted to ca. 7 by addition of 0.1 M HClO₄. The red crystals and orange precipitate that formed were dissolved by dilution of the mixture with H₂O and the whole was loaded onto a Sephadex SP C-25 cation exchange column and thoroughly washed with H₂O. Elution with 0.05 M then 0.1 M NaClO₄ eluted the major band, and concentration of the eluate by evaporation under reduced pressure produced red-brown crystals of [Co(TACN)(8-HQ)(CN)]ClO₄ (M7) (117 mg, 51%) which were collected and washed with a little ice cold H₂O then 3× with Et₂O. Anal. Calcd for C₁₆H₂₁N₅ClO₅Co: C, 41.98; H, 4.62; N, 15.30; Cl, 7.74. Found; C, 41.99; H, 4.44; N, 15.28; Cl, 7.93.

[0244] Biological Activity

[0245] Selected complexes of Table 1, together with the uncomplexed cytotoxic ligands, were evaluated for cytotoxicity (measured as IC₅₀ values in μM following a 4 h aerobic drug exposure) in a panel of mammalian cell lines, and the results are given in Table 2. AA8 is a Chinese hamster ovary line, and the UV4 cell line is a repair-defective ERCC-1 mutant, sensitive to agents whose cytotoxicity is due to bulky DNA adducts. EMT6 is a murine mammary carcinoma line, and SKOV3 is a human ovarian cancer line.

[0246] Table 2.

[0247] Shows the results of the biological activity for various cytotoxins and their metal complexes. IC₅₀ values are mean±sem (number of experiments in parentheses) for exposure of the indicated cell lines to compounds for 4 hr under aerobic conditions. TABLE 2 IC₅₀ (μM) Compound AA8 UV4 EMT6 SKOV3 Cytotoxic ligands 29  0.0058 ± 0.0007  0.0041 ± 0.0003 0.0028 0.0062 (2) (2) 0.0004 (2) 18a 0.00014 ± 0.000022 0.00007 ± 0.000015 0.000051 ± 0.000008 0.00025 ± 0.000037 (7) (6) (5) (8) 27  0.0079 ± 0.002  0.0029 ± 0.006  0.0026 ± 0.0005  0.012 ± 0.0023 (4) (4) (4) (4) 8-HQ   2.07 ± 0.02   2.16 ± 0.12   3.92 ± 1.04   4.07 ± 0.89 (3) (3) (2) (2) Ancillary ligands TACN (VIIIc:   12700 ± 5770   10100 ± 3930    7710 ± 1010   13500 ± 5480 R¹-R³ = H) (2) (2) (2) (2) Cyclen (IX; Z¹-Z⁴ = (CH₂)₂;   13300 ± 2670   13800 ± 2180    9710 ± 2710   11500 ± 4410 R^(1,)-R^(4,) = H) (2) (2) (3) (2) Metal complexes M1  0.0152 ± 0.0006  0.0051 ± 0.0002  0.0133 ± 0.0008  0.015 ± 0.005 (2) (2) (2) (3) M4  0.088 ± 0.017   0.03 ± 0.0018   0.039 ± 0.011   0.11 ± 0.018 (3) (3) (3) (3) M5  0.028 ± 0.003  0.015 ± 0.001  0.0095 ± 0.0012  0.016 ± 0.003 (3) (3) (2) (3) M7  5,670 ± 45.0  6,140 ± 820   3,580 ± 95.4  6,380 ± 1750 (2) (2) (2) (3)

[0248] The results of Table 2 show that the cytotoxic ligands 29, 18a and 27 are exceptionally cytotoxic. The results of Table 2 also show that metal complexation results in considerable abrogation of cytotoxicity, indicating the utility of this approach in forming less toxic prodrugs of these compounds.

[0249] Complex M1 listed in Table 1 was also evaluated for its ability to release the cytotoxic ligands when exposed to ionising radiation in deoxygenated sodium formate buffer (measured as G values in μM/Gy for radiolytic reduction, where the G value for total reductants is 0.68 μM/Gy), and the results are given in Table 3. TABLE 3 G values (μM/Gy) for release of cytotoxic ligand on radiolytic reduction in deoxygenated sodium formate buffer using 15 μM prodrug (complex M1). Cytotoxic Ancillary G value No Metal ligand ligands (μmol/Gy) M1 Co 18a Cyclen 0.75

[0250] The results of Table 3 show that certain of these metal complexes also have the potential to cleanly release their cytotoxic ligand in good yield following exposure to ionising radiation. As a specific example, FIG. 1 shows the release of cytotoxin 18a (SN 26800) from complex M1 (SN 27892) when irradiated in 0.1M sodium formate buffer pH 7.0 under hypoxic conditions.

[0251] It is thought that the mechanism of activation of the prodrug is as illustrated in the following mechanistic pathway.

[0252] The metal complexes also show an ability to be activated by endogenous enzymes under hypoxia, as shown for metal complex M1 in Table 4 and FIG. 2. Table 4 and FIG. 2 also show that the corresponding cytotoxic ligand 18a is not activated by endogenous enzymes under hypoxic conditions. Thus the metal complexes have utility as hypoxia- as well as radiation-activated cytotoxins. TABLE 4 Activation of metal complex M1 (but not the cytotoxin 18a) under hypoxia (4 h exposure). IC₅₀ (nM) A549 wt/s SKOV3 WiDr-2 oxic anoxic HCR oxic anoxic HCR oxic anoxic HCR 18a 0.050 ± 0.016(3) 0.050 ± 0.014(2) 0.79 ± 0.35(2) 0.25 ± 0.037(8) 0.35 ± 0.093(2) 0.61(1) — — — M1  5.60 ± 0.00(2)  0.38 ± 0.16(2) 18.0 ± 7.7(2) 15.0 ± 5.0(3)  1.7 ± 0.97(2) 8.1(1) 6.6 ± 0.45(2) 1.7 ± 0.10(2) 3.90 ± 0.50(2)

[0253] In Table 4, A549wt/s is a wild-type human colon carcinoma cell line, SKOV3 is a human ovarian cancer cell line and WiDr-2 is a clonal cell line derived from the WiDr human colon carcinoma line. IC₅₀s (in μM are determined under both oxic and hypoxic conditions, and the hypoxic cytotoxicity ratio (HCR) is the average intra-experiment ratio of the IC₅₀s measured under oxic and hypoxic conditions.

[0254] Wherein the foregoing description reference has been made to reagents, or integers having known equivalents thereof, then those equivalents are herein incorporated as if individually set forth.

[0255] While this invention has been described with reference to certain embodiments and examples, it is to be appreciated that further modifications and variations may be made to embodiments and examples without departing from the spirit or scope of the invention. 

What we claim is:
 1. A metal complex represented by Formula I

wherein: A is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; D is selected from C or N; E is selected from a direct bond, OH or NR¹ ₂, where each R¹ independently represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, when D represents C; or M is selected from Co^(III), Co^(II), Cr^(III) or Cr^(II); Z is selected from O, NR², where R² represents H or a C¹⁻⁶alkyl optionally substituted with one or more hydroxy or amino groups, S¹ and S² together represent formula V

wherein X is selected from a group including halogen, CH₂-halogen, CH₂OCO— (C₁₋₆alkyl optionally substituted with one or more amino or hydroxy groups), CH₂-phosphate group or CH₂OSO₂R³, where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and R is selected from one of formulae VI or VII

wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ or NHCOR⁵, where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4 and each R⁶ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and • represents the point of attachment of R to Formula V defined above, and S³ is selected from H, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or hydroxy groups]; OR⁷, NR⁷ ₂, or CONR⁷, where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or S³ represents an optionally substituted 5 or 6 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen groups, and wherein ligands L¹-L⁴ are each independently selected in combinations from anionic monodentate ligands, including CN⁻, SCN⁻, halide, NO₂ ⁻; bidentate ligands including MeCOCHJCOMe (Jacac; deprotonated in the complex), where J=H, Me, Cl, SMe, SO₂Me, S(CH₂)_(n)SO₃H, S(CH₂)_(n)CO₂H, S(CH₂)_(n)OP(O)(OH)₂, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H, CH₂(CH₂)_(n)OP(O)(OH)₂, S(CH₂)_(n)P(O)(OH)₂ or CH₂(CH₂)_(n)P(O)(OH)₂, where n is from 1-4; or tridentate ligands VIIIa-VIIIc (=respectively TACH, TAME and TACN when R¹-R₃═H).

wherein each R¹-R₄ are independently selected from H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂)_(n)P(O)(OH) or CH₂(CH₂)_(n)NR⁸ ₂, where each n is independently 1, 2, 3 or 4 and each R⁸ independently represents H, or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or L¹-L⁴ can also be selected from any one of the tetradentate ligands IX-XVII, or any two of the bidentate ligands XVIII, or any combination of the bidentate ligands XVIII together with any of the monodentate ligands L¹-L⁴ defined above;

wherein in formulae IX-XVIII, R^(1′) to R^(8′) each independently represent H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂)_(n)OP(O)((OH)₂ or CH₂(CH₂)_(n)NMe₂, where each n is independently 1, 2, 3 or 4; each Z¹-Z⁴ is independently selected from —(CH₂)₂—, —(CH₂)₃—, —CH₂OCH₂— or —CH₂N(R⁹CH₂—; where R⁹ represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and each Y′ is independently selected from H, halogen, SO₂Me, O(C₁-C₆alkyl), NR¹⁰ ₂, where each R¹⁰ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or Q¹(CH₂)_(n)Q², wherein Q¹ is selected from —O—, —CH₂—, —NH—, —CONH—, —CO₂— or —SO₂—, and Q² is selected from —CO₂H, —SO₃H, —OP(O)(OH)₂ or —NR¹¹ ₂ where each R¹¹ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and wherein the overall charge on the complex is neutral, positive or negative and wherein in the case of a non-neutral complex F^(countercharge) is selected from a range of physiologically acceptable-counterions, including halides⁻, NO₃ ⁻, NH₄ ⁺ or Na⁺; and wherein q is the required number to neutralise the overall charge on the complex; and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof.
 2. The metal complex according to claim 1 wherein the rings A and B of Formula I as defined in claim 1 together represent an 8-substituted quinoline system.
 3. The metal complex according to any claim 1 or claim 2 wherein Z represents —O—.
 4. The metal complex according to any claims 1 or 3 wherein Z represents —NH—.
 5. The metal complex according to any one of claims 1 to 4 wherein R is selected from one of


6. The metal complex according to any one of claims 1 to 5 wherein one of the ligands L¹-L⁴ is selected from the following


7. The metal complex according to any one of claims 1 to 6 wherein X is CH₂Cl.
 8. The metal complex according to any one of claims 1 to 7 selected from one of the following;


9. A method of providing cancer treatment, which includes the steps of (a) administering to a patient in need of such therapy an effective amount of a metal complex of Formula I as defined in any one of claims 1 to 8, and (a) activating the metal complex of Formula I under hypoxic conditions via reduction, either enzymatically or by a non-enzymatic endogenous reducing agents, or by ionizing radiation, wherein said activation releases a sufficient amount of an effector from said metal complex of Formula I.
 10. The method according to claim 9 including the alternative step of activation of the metal complex of Formula I as defined in any one of claims 1 to 8 by radiotherapy radiation.
 11. A composition comprising as an active agent a metal complex of Formula I as defined in any one of claims 1 to 8 and a pharmaceutically acceptable excipient, adjuvant or carrier.
 12. The use, in the manufacture of a medicament, of an effective amount of a metal complex of Formula I as defined in any one of claims 1 to 8 for use in treating a subject in need of cancer treatment.
 13. A metal complex represented by Formula Ia

wherein: A is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; D is selected from C or N; E is selected from a 5 or 6 membered ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups M is selected from Co^(III), Co^(II), Cr^(III) or Cr^(II); Z represents NH₂ or NHMe, Q represents H, C₁₋₆alkyl, or (CH₂)₂NH₂, when Q represents (CH₂)₂NH₂, Q will become a ligand for M and replace one of ligands L¹-L⁴ defined below, S¹ and S² together represent formula V

wherein X is selected from a group including halogen, CH₂-halogen, CH₂CN, CH₂CO₂—(C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups), CH₂-phosphate group, CH₂OSO₂R³ or OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and R is selected from one of formulae VI or VII

wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR², NR² ₂ where each R² independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR³ ₂, where each n is independently 1, 2, 3 or 4, and each R³ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and • represents the point of attachment of R to Formula V defined above, and S³ is selected from H, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or halogen groups, OR⁴, NR⁴ ₂, CONHR⁴, where each R⁴ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen groups, and wherein ligands L¹-L⁴ are each independently selected in combinations from anionic monodentate ligands, including CN⁻, SCN⁻, halide, NO₃ ⁻; bidentate ligands including MeCOCHJCOMe (Jacac; deprotonated in the complex), where J=H, Me, Cl, SMe, SO₂Me, S(CH₂)_(n)SO₃H S(CH₂)_(n)CO₂H, S(CH₂)_(n)OP(O)(OH)₂, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H, CH₂(CH₂)_(n)OP(O)(OH)₂, S(CH₂)_(n)P(O)(OH)₂ CH₂(CH₂)_(n)P(O)(OH)₂, or where each n is independently 1, 2, 3 or 4; or tridentate ligands VIIIa-VIIIc (=respectively TACH, TAME and TACN when R¹-R₃═H),

wherein R¹-R⁴ are each independently selected from H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂))_(n)OP(O)(OH)₂ CH₂(CH₂)_(n)P(O)(OH)₂ or CH₂(CH₂)_(n)NR⁵ ₂, where each n is independently 1, 2, 3 or 4 and each R⁵ independently represents H, or a C₁₋₆allyl optionally substituted with one or more hydroxy or amino groups or L¹-L⁴ can also be selected from any one of the tetradentate ligands IX-XVII, or any two of the bidentate ligands XVIII, or any combination of the bidentate ligands XVIII together with any of the monodentate ligands L¹-L⁴ defined above;

wherein in formulae IX-XVIII, R^(1′) to R^(8′) each independently represent H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂)_(n)OP(O)(OH)₂ or CH₂(CH₂)_(n)NMe₂, where each n is independently 1, 2, 3 or 4; each Z¹-Z⁴ is independently selected from —(CH₂)₂—, —(CH₂)₃—, —CH₂OCH₂— or —CH₂N(R⁶)CH₂—; where R⁶ represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and each Y′ is independently selected from H, halogen, SO₂Me, O(C₁-C₆alkyl), NR⁷ ₂, where each R⁷ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or Q¹(CH₂)_(n)Q², wherein Q¹ is selected from —O—, —CH₂—, —NH—, —CONH—, —CO₂— or —SO₂— and Q² is selected from —CO₂H, —SO₃H, —OP(O)(OH)₂ or —NR₈ ₂ where each R⁸ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and wherein the overall charge on the complex is neutral, positive or negative and wherein in the case of a non-neutral complex F^(countercharge) is selected from a range of physiologically acceptable-counterions, including halide⁻, NO₃ ⁻, NH₄ ⁺ or Na⁺; and wherein q is the required number to neutralise the overall charge on the complex; and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof.
 14. The metal complex according to claim 13 wherein rings A and B together represent an 8-substituted quinoline system
 15. The metal complex according to claim 13 or claim 14 wherein Z represents —OH.
 16. The metal complex according to claim 13 or claim 14 wherein Z represents —NH.
 17. The metal complex according to any one of claims 13 to 16 wherein R is selected from one of


18. The metal complex according to any one of claims 13 to 17 wherein one of the ligands L¹-L⁴ is selected from the following


19. The metal complex according to any one of claims 13 to 18 wherein X is CH₂Cl.
 20. The metal complex according to any one of claims 13 to 17 and 19 which represents


21. A method of providing cancer treatment, which includes the steps of (a) administering to a patient in need of such therapy an effective amount of a metal complex of Formula Ia as defined in any one of claims 13 to 20, and (b) activating the compound of Formula Ia under hypoxic conditions via reduction, either enzymatically or by non enzymatic endogenous reducing agents, or by ionising radiation, wherein said activation releases a sufficient amount of an effector, from said effective amount of the compound of Formula Ia.
 22. The method according to claim 21 including the alternative step of activation of the metal complex of Formula Ia as defined in any one of claims 13 to 20 by radiotherapy radiation.
 23. A composition comprising as an active agent a metal complex of Formula Ia as defined in any one of claims 13 to 20 and a pharmaceutically acceptable excipient, adjuvant or carrier. 24 The use, in the manufacture of a medicament, of an effective amount of a compound of Formula Ia as defined in any one of claims 13 to 20 for use in treating a subject in need of cancer treatment.
 25. A heterocyclic compound of Formula XIX.

wherein A is selected from a 5 or 6 membered ring system optionally containing one or more additional heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; Z is selected from OH or NR¹ ₂, where each R¹ independently represents H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups; S¹ and S² together represent formula V

wherein X is selected from a leaving group including halogen, CH₂-halogen, CH₂CN, CH₂CO₂—(C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups), CH₂-phosphate group, CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and R is selected from one of formulae VI or VII

wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4 and each R⁶ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; • represents the point of attachment to Formula XIX defined above; S³ is selected from H, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or hydroxy groups], OR⁷, NR⁷ ₂, CONHR⁷ where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen groups; and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof, with the proviso that when Z, A, B, X, S¹, S² and S³ together represent

R does not represent one of the following

26 The heterocyclic compound according to claim 25 wherein the rings A and B together represent an 8-substituted quinoline system.
 27. The heterocyclic compound according to claim 25 or claim 26 wherein Z represents —OH.
 28. The heterocyclic compound according to any one of claims 25 to 27 wherein Z represents —NH₂.
 29. The heterocyclic compound according to any one of claims 25 to 28 wherein R is selected from one of


30. The heterocyclic compound according to any one of claims 25 to 29 wherein X is —CH₂Cl.
 31. The heterocyclic compound according to any one of claims 25 to 30 selected from one of the following 1-(chloromethyl)-5-hydroxy-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-3-({5-[2-(dimethylamino)ethoxy]-indol -2-yl}carbonyl)-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-3-((2E)-3-{4-[2-(dimethylamino)ethoxy]phenyl}-2-propenoyl)-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(5-methoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(2E)-3-(4-methoxyphenyl)-2-propenoyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(2E)-3-(3-hydroxy-4-methoxyphenyl)-2-propenoyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline and, 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline.
 32. A method of providing cancer treatment, which includes the step of administering to a patient in need of such therapy an effective amount of a heterocyclic compound of Formula XIX, as defined in any of claims 25-31.

wherein A is selected from a 5 or 6 membered ring system optionally containing one or more additional heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; B is selected from a 5 or 6membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; Z is selected from OH or NR¹ ₂, where each R¹ independently represents H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups; S¹ and S² together represent formula V

wherein X is selected from a leaving group including halogen, CH₂-halogen, CH₂CN, CH₂-phosphate group, CH₂CO₂R², where R² represents C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups; CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydrogen or amino groups; and R is selected from one of formulae VI or VII

wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4 and each R⁶ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; • represents the point of attachment to Formula XIX defined above; S³ is selected from H, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino or hydroxy groups], OR⁷, NR⁷ ₂, CONHR⁷ where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen group; and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof.
 33. The method according to claim 32 wherein the rings A and B of Formula XIX together represent an 8-substituted quinoline system.
 34. The method according to claim 32 or claim 33 wherein Z of Formula XIX represents —OH.
 35. The method according to any one of claims 32 to 34 wherein Z of Formula XIX represents —NH₂.
 36. The method according to any one of claims 32 to 35 wherein R of Formula XIX is selected from one of


37. The method according to any one of claims 32 to 36 wherein X of Formula XIX is —CH₂Cl.
 38. The method according to any one of claims 32 to 37 wherein Formula XIX is selected from one of the following 1-chloromethyl)-5-hydroxy-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-3-({5-[2-(dimethylamino)ethoxy]-indol-2-yl}carbonyl)-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-chloromethyl)-3-((2E)-3-{4-[2-(dimethylamino)ethoxy]phenyl}-2-propenoyl)-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(5-methoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(2E)-3-(4-methoxyphenyl)-2-propenoyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(2E )-3-(3-hydroxymethoxyphenyl)-2-propenoyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline and, 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline.
 39. A composition comprising as an active agent a compound of Formula XIX

wherein A is selected from a 5 or 6 membered ring system optionally containing one or more additional heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or ammo groups; B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; Z is selected from OH or NR¹ ₂, where each R¹ independently represents H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups; Z is selected from O or NR¹, where R¹ represents H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups; S¹ and S² together represent formula V

wherein X is selected from a leaving group including halogen, CH₂-halogen, CH₂CN, CH₂-phosphate group, CH₂CO₂R², where R² represents C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups; CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁴ where R⁴ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and R is selected from one of formulae VI or VII

wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4 and each R⁶ is independently selected from H or a C₁₋₆allyl optionally substituted with one or more hydroxy or amino groups; • represents the point of attachment to Formula XIX defined above; S³ is selected from H, OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or hydroxy groups], OR⁷, NR⁷, CONHR⁷ where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆allyl, C₁₋₆alkoxy, and halogen groups; and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof and a pharmaceutically acceptable excipient, adjuvant or carrier.
 40. The composition according to claim 39 wherein the rings A and B of Formula XIX together represent an 8-substituted quinoline system.
 41. The composition according to claim 39 or claim 40 wherein Z of Formula XIX represents —OH.
 42. The composition according to any one of claims 39 to 41 wherein Z of Formula XIX represents —NH₂.
 43. The composition according to any one of claims 39 to 42 wherein R of Formula XIX is selected from one of


44. The composition according to any one of claims 39 to 43 wherein X of Formula XIX is —CH₂Cl.
 45. The composition according to any one of claims 39 to 44 wherein Formula XIX represents one of the following 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-3-({5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl}carbonyl)-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-3-((2E)-3-{4-[2-(dimethylamino)ethoxy]phenyl}-2-propenoyl)-5-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(5-methoxy-1H-indol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(2E)-3-(4-methoxyphenyl)-2-propenoyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(2E)-3-(3-hydroxy-4-methoxyphenyl)-2-propenoyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, and 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline.
 46. The use, in the manufacture of a medicament, of an effective amount of a compound of Formula XIX

wherein A is selected from a 5 or 6 membered ring system optionally containing one or more additional heteroatoms and optionally substituted with one or more C₁₋₆allyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; B is selected from a 5 or 6 membered aromatic ring system optionally containing one or more heteroatoms and optionally substituted with one or more C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, phosphate, cyano or amino groups; Z is selected from OH or NR¹ ₂, where each R¹ independently represents H or C₁-C₆alkyl optionally substituted with one or more amino, hydroxy, a halogen or cyano groups;

wherein X is selected from a leaving group including halogen, CH₂-halogen, CH₂CN, CH₂-phosphate group, CH₂CO₂R², where R² represents C₁-C₆alkyl optionally substituted with one or more amino or hydroxy groups; CH₂OSO₂R³ where R³ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or CH₂OSO₂NHR⁵ where R¹ represents H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; and R is selected from one of formulae VI or VII

wherein each T₁, T₂ and T₃ is independently selected from H, OPO(OH)₂, OR⁵, NR⁵ ₂ where each R⁵ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or O(CH₂)_(n)NR⁶ ₂, where each n is independently 1, 2, 3 or 4, and each R⁶ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; • represents the point of attachment to Formula XIX defined above; S³ is selected from H, OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, CO₂[(C₁₋₆alkyl) wherein said alkyl is optionally substituted with amino, or hydroxy groups], OR⁷, NR⁷, CONHR⁷ where each R⁷ independently represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups; or S³ represents an optionally substituted 4-8 membered cyclic system optionally containing one or more heteroatoms fused to ring system A defined above, wherein said substituents are selected from OH, cyano, phosphate, amino, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen groups, and including any enantiomeric or diastereomeric form, and any physiologically salt derivative thereof, for use in treating a subject in need of cancer treatment
 47. The use according to claim 46 wherein the rings A and B of Formula XIX together represent an 8-substituted quinoline system.
 48. The use according to claim 46 or claim 47 wherein Z of Formula XIX represents —OH.
 49. The use according to any one of claims 46 to 48 wherein Z of Formula XIX represents —NH₂.
 50. The composition according to any one of claims 46 to 49 wherein R of Formula XIX is selected from one of

51 The composition according to any one of claims 46 to 50 wherein X of Formula XIX is —CH₂Cl.
 52. The composition according to any one of claims 46 to 51 wherein Formula XIX represents one of the following 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbony)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-chloromethyl)-5-hydroxy-({5-[2dimethylamino)ethoxy]-1H-indol-2-yl}carbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-3-((2E)-3-{4-[2-(dimethylamino)ethoxy]phenyl}-5-hydroxy-2-propenoyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(5-methoxy-1H-indol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-5-hydroxy-3-[(2E)-3-(4-methoxyphenyl)-2-propenoyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline, 1-(chloromethyl)-3-[(2E)-3-(3-hydroxy-4-methoxyphenyl)-2-propenoyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline-5-ol, and 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline. enantiomeric or diastereomeric forms, or any mixtures of such forms, and also any physiologically functional salt derivatives thereof.
 53. A method of preparing a metal complex according to any one of claims 1 to 8 or 13 to 20, including the step of coupling a heterocyclic compound defined in any one of claims 25 to 31 with one or more of ligands L¹-L⁴, wherein ligands L¹-L⁴ are each independently selected in combinations from anionic monodentate ligands, including CN⁻, SCN⁻, halide, NO₃ ⁻; bidentate ligands including MeCOCHJCOMe (Jacac; deprotonated in the complex), where J=H, Me, Cl, SMe, SO₂Me, S(CH₂)_(n)SO₃H, S(CH₂)_(n)CO₂H, S(CH₂)_(n)OP(O)(OH)₂, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H, S(CH₂)_(n)P(O)(OH)₂ or CH₂(CH₂)_(n)P(O)(OH)₂, where each n is independently 1, 2, 3 or 4; or tridentate ligands VIIIa-VIIIc (=respectively TACH, TAME and TACN when R₁-R₃═H),

wherein R₁-R₄ are each independently selected from H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂)_(n)OP(O)(OH)₂ CH₂(CH₂)_(n)P(O)(OH)₂ or CH₂(CH₂)_(n)NR⁵ ₂, where each n is independently 1, 2, 3 or 4 and each R⁵ independently represents H, or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups or L¹-L⁴ can also be selected from any one of the tetradentate ligands IX-XVII, or any two of the bidentate ligands XVII, or any combination of the bidentate ligands XVIII together with any of the monodentate ligands L¹-L⁴ defined above;

wherein in formulae IX-XVIII, R^(1′) to R^(8′) each independently represent H, Me, CH₂(CH₂)_(n)SO₃H, CH₂(CH₂)_(n)CO₂H or CH₂(CH₂)_(n)OP(O)(OH)₂ or CH₂(CH₂)_(e)NM₂, where each n is independently 1, 2, 3 or 4; each Z¹-Z⁴ is independently selected from —(CH₂)₂—, —(CH₂)₃—, —CH₂OCH₂— or —CH₂N(R⁶)CH₂—; where R⁶ represents H, a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups and each Y′ is independently selected from H, halogen, SO₂Me, O(C₁-C₆alkyl), NR⁷ ₂, where each R⁷ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, or Q¹(CH₂)_(n)Q², wherein Q¹ is selected from—O—, —CH₂—, —NH—, —CONH—, —CO₂— or —SO₂—, and Q² is selected from —CO₂H, —SO₃H, —OP(O)(OH)₂ or —NR⁸ ₂ where each R⁸ is independently selected from H or a C₁₋₆alkyl optionally substituted with one or more hydroxy or amino groups, and wherein the ligands are complexed with a metal selected from Co^(III), Co^(II), Cr^(III) or Cr^(II).
 54. A method of preparing a heterocyclic compound as defined in any one of claims 25 to 32, including the following reaction pathway


55. The method according to claim 54 including the further steps represented by the pathway 